<!DOCTYPE html> <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy - Martinez‐Zapata, MJ - 2014 | Cochrane Library</title> <meta property="og:title" content="Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy - Martinez‐Zapata, MJ - 2014 | Cochrane Library" /> <meta property="og:url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008721.pub2/references" /> <meta property="og:type" content="article" /> <meta property=”og:image” content=”https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png” /> <meta content="initial-scale=1.0, width=device-width" name="viewport" /> <meta name="dc.identifier" scheme="DOI" content="10.1002/14651858.CD008721.pub2" /> <meta name="citation_title" content="Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy" /> <meta name="citation_author" content="Maria Jos&eacute; Martinez‐Zapata" /> <meta name="citation_author_institution" content="CIBER Epidemiolog&iacute;a y Salud P&uacute;blica (CIBERESP)" /> <meta name="citation_author_email" content="mmartinezz@santpau.cat" /> <meta name="citation_author" content="Arturo J Mart&iacute;‐Carvajal" /> <meta name="citation_author_institution" content="Iberoamerican Cochrane Network" /> <meta name="citation_author" content="Ivan Sol&agrave;" /> <meta name="citation_author_institution" content="CIBER Epidemiolog&iacute;a y Salud P&uacute;blica (CIBERESP)" /> <meta name="citation_author" content="Jos&eacute; I Pijo&aacute;n" /> <meta name="citation_author" content="Jos&eacute; A Buil‐Calvo" /> <meta name="citation_author_institution" content="Hospital de la Santa Creu i Sant Pau" /> <meta name="citation_author" content="Josep A Cordero" /> <meta name="citation_author_institution" content="Universitat Ramon Llull" /> <meta name="citation_author" content="Jennifer R Evans" /> <meta name="citation_author_institution" content="London School of Hygiene &amp; Tropical Medicine" /> <meta name="citation_journal_title" content="Cochrane Database of Systematic Reviews" /> <meta name="citation_publisher" content="John Wiley &amp; Sons, Ltd" /> <meta name="citation_issue" content="11" /> <meta name="citation_doi" content="10.1002/14651858.CD008721.pub2" /> <meta name="citation_date" content="2014" /> <meta name="citation_online_date" content="2014/11/24" /> <meta name="citation_abstract_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008721.pub2/abstract" /> <meta name="citation_fulltext_html_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008721.pub2/full" /> <meta name="citation_pdf_url" content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008721.pub2/pdf/CDSR/CD008721/CD008721.pdf" /> <meta name="citation_issn" content="1465-1858" /> <meta name="citation_language" content="en" /> <meta name="citation_keywords" content="Antibodies, Monoclonal, Humanized [therapeutic use]; Aptamers, Nucleotide [therapeutic use]; Bevacizumab; Diabetic Retinopathy [*drug therapy, surgery]; Light Coagulation [methods]; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A [*therapeutic use]; Visual Acuity [drug effects]; Vitrectomy; Vitreoretinopathy, Proliferative [*drug therapy, surgery]" /> <script type="text/javascript" src="//script.crazyegg.com/pages/scripts/0056/6375.js" async="async"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <script type="text/javascript">var o={auth:{customerIds:["P#DRAAEAC","EAL00000056729","DRAA3TITLES","TSINGH009S","EAL0001468","EAL00000045347"],individualId:null,brandedCustomer:"EAL0001468",roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=UTF-8" http-equiv="content-type" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/favicon.ico" rel="Shortcut Icon" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" rel="canonical" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-CN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;zh_TW&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="zh-TW" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;hr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="hr-HR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="x-default" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="en-US" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fr&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fr-FR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;de&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="de-DE" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ja&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ja-JP" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ko&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ko-KR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ms&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ms-MY" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;fa&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="fa-IR" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pl&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pl-PL" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;pt&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="pt-PT" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ru&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ru-RU" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;es&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="es-ES" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;ta&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="ta-IN" rel="alternate" /> <link href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;th&#x2f;content&#x3f;templateType&#x3d;references&#x26;urlTitle&#x3d;&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;doi&#x3d;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x26;type&#x3d;cdsr&#x26;contentLanguage&#x3d;" hreflang="th-TH" rel="alternate" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;aui&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <link href="&#x2f;html&#x2f;css&#x2f;main&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1513680834000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" rel="stylesheet" type="text/css" /> <link href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1581718256000" rel="stylesheet" type="text/css" /> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 13},getRevision:function(){return"605.1"},getVersion:function(){return"13.0"},isAir:function(){return false},isChrome:function(){return false},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return false},isMac:function(){return true},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EfT7x5RD";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dreferences\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008721\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008721\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article References"},article:{availableLanguage:["en","es","ru"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008721.pub2",title:"Anti\\u2010vascular endothelial growth factor for proliferative diabetic retinopathy",firstPublishedDate:"Nov 24, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;cochrane-theme&#x2f;css&#x2f;custom&#x2e;css&#x3f;browserId&#x3d;other&#x26;themeId&#x3d;cochrane_WAR_cochranetheme&#x26;minifierType&#x3d;css&#x26;languageId&#x3d;en_US&#x26;b&#x3d;6210&#x26;t&#x3d;1581422282000" rel="stylesheet" type="text/css" /> <style type="text/css"></style> <script src="//assets.adobedtm.com/6e626c9ec247e474f6b98eb15a79a185cf7e26a5/satelliteLib-b0f13d7a13ebe8b0b1b00a9f0730a084926e292f.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1581422282000" type="text/javascript"></script> <![endif]--> </head> <body class=" yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div id="js-cookie-message" class="cookie-message cookie-message--hidden system-message-container"> <div class="container"> <a href="#" class="fa fa-times js-cookie-close pull-right" aria-label="Close cookies message"></a> <div class="system-message-wrapper container"> <i class="fa fa-exclamation-triangle" aria-hidden="true"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/N7XGCZUQPW4C675JNSTYTLUDN7XB/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a href="#" class="btn secondary js-cookie-close js-cookie-accept">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/"> <span class="brand-name">The Cochrane Library</span> <img class="brand-logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_logo.png" alt="Cochrane Library logo" title="Cochrane Library" /> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="owel__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008721.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008721.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a href="/en/browse-by-topic" class="btn secondary">Browse</a>
<a href="/en/advanced-search" class="btn primary advanced-search-button">Advanced search</a>
</div>
</div>
<a href="#" class="toggle-menu-switch"><i class="fa fa-bars" aria-hidden="true"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<p class="auxiliary-menu-item access">Access provided by: <strong>Tsinghua University</strong></p>
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="bvrs__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="open-language-modal" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="language-selector-modal-content" style="display: none;" data-modal-title="Language selection" data-size="large"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div> <a href="/en/cdsr/doi/10.1002/14651858.CD008721.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD008721.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <button class="btn primary btn-cancel" type="button">Cancel</button> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008721.pub2%2Freferences" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
</a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
<div class="access-provider-mobile">
<p class="access">Access provided by: <strong>Tsinghua University</strong></p>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class=" nav-root-item parent">
<a href="#">Cochrane Reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_14" role="presentation">
<a aria-labelledby="layout_14" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews" role="menuitem">
Search Reviews (CDSR)
</a>
</li>
<li class=" child-nav-item" id="layout_15" role="presentation">
<a aria-labelledby="layout_15" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;reviews&#x2f;topics" role="menuitem">
Browse Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_18" role="presentation">
<a aria-labelledby="layout_18" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;table-of-contents" role="menuitem">
Issues
</a>
</li>
<li class=" child-nav-item" id="layout_17" role="presentation">
<a aria-labelledby="layout_17" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;editorials" role="menuitem">
Editorials
</a>
</li>
<li class=" child-nav-item" id="layout_19" role="presentation">
<a aria-labelledby="layout_19" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;special-collections" role="menuitem">
Special Collections
</a>
</li>
<li class=" child-nav-item" id="layout_20" role="presentation">
<a aria-labelledby="layout_20" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;supplements" role="menuitem">
Supplements
</a>
</li>
<li class=" child-nav-item" id="layout_13" role="presentation">
<a aria-labelledby="layout_13" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cdsr&#x2f;about-cdsr" role="menuitem">
About the CDSR
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_22" role="presentation">
<a aria-labelledby="layout_22" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central" role="menuitem">
Search Trials (CENTRAL)
</a>
</li>
<li class=" child-nav-item" id="layout_114" role="presentation">
<a aria-labelledby="layout_114" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;central&#x2f;about-central" role="menuitem">
About CENTRAL
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_29" role="presentation">
<a aria-labelledby="layout_29" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca" role="menuitem">
Browse Clinical Answers
</a>
</li>
<li class=" child-nav-item" id="layout_91" role="presentation">
<a aria-labelledby="layout_91" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;cca&#x2f;about" role="menuitem">
About Clinical Answers
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_116" role="presentation">
<a aria-labelledby="layout_116" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-library" role="menuitem">
About the Cochrane Library
</a>
</li>
<li class=" child-nav-item" id="layout_34" role="presentation">
<a aria-labelledby="layout_34" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochrane&#x2e;org&#x2f;about-us" role="menuitem">
About Cochrane
</a>
</li>
<li class=" child-nav-item" id="layout_121" role="presentation">
<a aria-labelledby="layout_121" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;about-cochrane-reviews" role="menuitem">
About Cochrane Reviews
</a>
</li>
<li class=" child-nav-item" id="layout_92" role="presentation">
<a aria-labelledby="layout_92" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;author-information" role="menuitem">
Information for authors
</a>
</li>
<li class=" child-nav-item" id="layout_188" role="presentation">
<a aria-labelledby="layout_188" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;releases" role="menuitem">
What&#039;s new
</a>
</li>
</ul>
</li>
<li class=" nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class=" child-nav-item" id="layout_177" role="presentation">
<a aria-labelledby="layout_177" href="https&#x3a;&#x2f;&#x2f;www&#x2e;wiley&#x2e;com&#x2f;network&#x2f;cochranelibrarytraining" role="menuitem">
Cochrane Library Training
</a>
</li>
<li class=" child-nav-item" id="layout_44" role="presentation">
<a aria-labelledby="layout_44" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;access" role="menuitem">
Access options
</a>
</li>
<li class=" child-nav-item" id="layout_150" role="presentation">
<a aria-labelledby="layout_150" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;permissions" role="menuitem">
Permissions and reprints
</a>
</li>
<li class=" child-nav-item" id="layout_93" role="presentation">
<a aria-labelledby="layout_93" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;media" role="menuitem">
Media information
</a>
</li>
<li class=" child-nav-item" id="layout_97" role="presentation">
<a aria-labelledby="layout_97" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;help&#x2f;contact-us" role="menuitem">
Contact us
</a>
</li>
<li class=" child-nav-item" id="layout_125" role="presentation">
<a aria-labelledby="layout_125" href="https&#x3a;&#x2f;&#x2f;www&#x2e;cochranelibrary&#x2e;com&#x2f;en&#x2f;about&#x2f;terms-and-conditions" role="menuitem">
Terms and conditions
</a>
</li>
<li class=" child-nav-item" id="layout_176" role="presentation">
<a aria-labelledby="layout_176" href="https&#x3a;&#x2f;&#x2f;hub&#x2e;wiley&#x2e;com&#x2f;docs&#x2f;cochrane-library&#x2f;cochrane-library-known-issues-DOC-16221&#x3f;referrer&#x3d;cochrane" role="menuitem">
Known issues
</a>
</li>
</ul>
</li>
<li class="about-link"><a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img id="etlj__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <section class="content-language-banner system-message-container" data-content-language="en" data-portal-language="en" style="display: none"> <div class="container"> <a href="#0" class="fa fa-times content-language-banner-close pull-right" aria-label="Close"></a> <i class="fa fa-globe" aria-hidden="true"></i> <div class="system-message-title">Content Language Selection</div> <div class="system-message-description">Your language preference is set to <strong class="language">English</strong>. Where translations are available, article sections will display in this language. Return to <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=reset-content-language&p_p_cacheability=cacheLevelPage" class="language secondary">English</a>.</div> </div> </section> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div id="content" class="">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="rjus__column1__0" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools"> <li class="cdsr-nav-link pulldown-menu readcube-menu closed"> <a href="#0" class="pulldown-menu-trigger"> <i class="icon fa fa-file-pdf-o"></i>View PDF <i aria-hidden="true" class="fa fa-caret-up"></i> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/pdf/full/en" class="download media pdf-link-full pdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/epdf/full/en" class="download media pdf-link-full readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Full </span> <span class="readcube-description "> All content </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/pdf/standard/en" class="download media pdf-link-standard pdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/epdf/standard/en" class="download media pdf-link-standard readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Standard </span> <span class="readcube-description "> Excludes data and analyses, and appendices </span> </a> </li> <li class=""> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/pdf/abstract/en" class="download media pdf-link-abstract pdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/epdf/abstract/en" class="download media pdf-link-abstract readcube-epdf-link" title="Article in PDF format"> <span class="readcube-label "> Summary </span> <span class="readcube-description "> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="cdsr-nav-link cite-article-link" data-article-id="CD008721.PUB2" data-modal-title="Cite this Review"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/#"> <i class="icon fa fa-share"></i>Cite this Review </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-english-only-message="Please note, that requesting permissions is available in English only. Apologies for any inconvenience." href="/cdsr/doi/10.1002/14651858.CD008721.pub2/#" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false"> <span class="request-permissions-icon"></span> Request Permissions </a> </li> <li class="cdsr-nav-link comment-on-review"> <a id="comment-on-review" class="js-old-version-modal-trigger" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/comment" data-new-version="" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience."> <i class="icon fa fa-comment"></i>Comment on Review </a> </li> <li class="cdsr-nav-link comment-on"> <span>Read comments on this Review(0)</span> </li> </ul> <ul class="share clearfix"> <li class="cdsr-nav-link print-cdsr-link" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008721.pub2/print" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Data and analysis&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;}]}]"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/#"> <i class="icon fa fa-print"></i>Print </a> </li> <li class="cdsr-nav-link share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008721.pub2/full"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/#"> <i class="icon fa fa-share-alt"></i>Share </a> </li> <li class="cdsr-nav-link"> <a href="/c/portal/login" class="article-not-followed cochrane-link signin"> <span class="article-follow-display"><i class="icon fa fa-plus"></i>Follow</span> </a> </li> </ul> <ul id="linked-articles" data-type="cdsr" class="linked-content tools clearfix linked-content-trigger"> <li> <a href="#0"> <span class="linked-to-this"> Linked to this Review <span class="linked-content-count"></span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> </li> </ul> <ul class="linked-content-dropdown"> <li data-type="cca" class="linked-cca"> <p>Cochrane Clinical Answers</p> </li> <li data-type="editorial" class="linked-editorials"> <p>Editorials</p> </li> <li data-type="podcast" class="linked-podcasts"> <p>Podcasts</p> </li> <li data-type="sc" class="linked-sc"> <p>Special Collections</p> </li> </ul> <ul class="nav-long-form"> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-sec1-0006"> Discussion </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/appendices#CD008721-sec1-0012"> Appendices </a> </li> </ul> <ul> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/information"> Information </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/information#authors"> Authors </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/information#history"> History </a> </li> <li class="cdsr-nav-link article-section-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/information#keywords"> Keywords </a> </li> </ul> <ul> <li class="cdsr-nav-link bold-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/#"> <i class="icon fa fa-globe"></i>Translation notes </a> </li> </ul> <ul> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references"> References </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link references-link"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#dataAndAnalyses"> Data and analyses </a> </li> </ul> <ul class="tools"> <li class="cdsr-nav-link "> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/#"> <i class="icon fa fa-line-chart"></i>Figures and tables </a> </li> <li class="cdsr-nav-link download-stats-data-link " data-download-href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/table_n/CD008721StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/table_n/CD008721StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <i class="icon fa fa-download"></i>Download statistical data </a> </li> <li class="cdsr-nav-link "> <a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i>Related content <span class="note podcast-indicator">Podcast available</span> </a> </li> </ul> </nav> </div> <article class="information" data-article-id="CD008721.PUB2"> <header> <h1 class="publication-title"><h1 lang="en" class="publication-title">Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy</h1></h1> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div><h2 class="title section-collapse-title"> References <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <section class="references bibliographies" id="references"> <section> <div class="section-header" id="CD008721-bbs1-0001"> <h3 class="title">References to studies included in this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008721-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0004">additional references</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0001"> <div class="reference-title-banner"> <h4 class="title">Ahmadieh 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0001"> <div class="citation-journal">Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. <span class="citation-title">Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(10):1943‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19699531" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+for+prevention+of+early+postvitrectomy+hemorrhage+in+diabetic+patients:+a+randomized+clinical+trial+&author=H+Ahmadieh&author=N+Shoeibi&author=M+Entezari&author=R+Monshizadeh&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0002"> <div class="reference-title-banner"> <h4 class="title">Ahn 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0002"> <div class="citation-journal">Ahn J, Woo SJ, Chung H, Park KH. <span class="citation-title">The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2011</span>;<span class="volume">118</span>(11):2218‐26. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21724263" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+effect+of+adjunctive+intravitreal+bevacizumab+for+preventing+postvitrectomy+hemorrhage+in+proliferative+diabetic+retinopathy+&author=J+Ahn&author=SJ+Woo&author=H+Chung&author=KH+Park&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0003"> <div class="reference-title-banner"> <h4 class="title">Cheema 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0003"> <div class="citation-journal">Cheema RA, Al‐Mubarak MM, Amin YM, Cheema MA. <span class="citation-title">Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study</span>. <span class="citation"> Journal of Cataract and Refractive Surgery </span><span class="pubYear">2009</span>;<span class="volume">35</span>(1):18‐25. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19101420" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Role+of+combined+cataract+surgery+and+intravitreal+bevacizumab+injection+in+preventing+progression+of+diabetic+retinopathy:+prospective+randomized+study+&author=RA+Cheema&author=MM+Al%E2%80%90Mubarak&author=YM+Amin&author=MA+Cheema&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0004"> <div class="reference-title-banner"> <h4 class="title">Cho 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0004"> <div class="citation-journal">Cho WB, Moon JW, Kim HC. <span class="citation-title">Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">94</span>(7):858‐63. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20606024" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+triamcinolone+and+bevacizumab+as+adjunctive+treatments+to+panretinal+photocoagulation+in+diabetic+retinopathy+&author=WB+Cho&author=JW+Moon&author=HC+Kim&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0005"> <div class="citation-journal">Cho WB, Oh SB, Moon JW, Kim HC. <span class="citation-title">Panretinal photocoagulation combined with intravitreal bevacizumab in high‐risk proliferative diabetic retinopathy</span>. <span class="citation"> Retina </span><span class="pubYear">2009</span>;<span class="volume">29</span>(4):516‐22. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19262436" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Panretinal+photocoagulation+combined+with+intravitreal+bevacizumab+in+high%E2%80%90risk+proliferative+diabetic+retinopathy+&author=WB+Cho&author=SB+Oh&author=JW+Moon&author=HC+Kim&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0005"> <div class="reference-title-banner"> <h4 class="title">Di Lauro 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0006"> <div class="citation-journal">Lauro R, Ruggiero P, Lauro MT, Romano MR. <span class="citation-title">Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy</span>. <span class="citation"> Graefe's Archive for Clinical and Experimental Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">248</span>(6):785‐91. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20135139" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+for+surgical+treatment+of+severe+proliferative+diabetic+retinopathy&author=R+Lauro&author=P+Ruggiero&author=MT+Lauro&author=MR+Romano&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0006"> <div class="reference-title-banner"> <h4 class="title">DRCR.Net 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0007"> <div class="citation-journal">Diabetic Retinopathy Clinical Research Network. <span class="citation-title">Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy</span>. <span class="citation"> JAMA Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">131</span>(3):283‐93. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23370902" target="_blank"> <span>PubMed</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0007"> <div class="reference-title-banner"> <h4 class="title">El‐Batarny 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0008"> <div class="citation-journal">El‐Batarny AM. <span class="citation-title">Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy</span>. <span class="citation"> Clinical Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">2</span>(4):709‐16. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19668420" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+as+an+adjunctive+therapy+before+diabetic+vitrectomy&author=AM+El%E2%80%90Batarny&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0008"> <div class="reference-title-banner"> <h4 class="title">Ergur 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0009"> <div class="citation-journal">Ergur O, Bayhan HA, Kurkcuoglu P, Takmaz T, Gurdal C, Can I. <span class="citation-title">Comparison of panretinal photocoagulation (PRP) with PRP plus intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy</span> [Proliferatif diyabetik retinopati tedavisinde tek basina panretinal fotokoagulasyon (PRF) ile PRF ve intravitreal bevacizumab kombinasyonunun karsilastirilmasi]. <span class="citation"> Retina‐Vitreus </span><span class="pubYear">2009</span>;<span class="volume">17</span>(4):273‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Comparison+of+panretinal+photocoagulation+(PRP)+with+PRP+plus+intravitreal+bevacizumab+in+the+treatment+of+proliferative+diabetic+retinopathy+&author=O+Ergur&author=HA+Bayhan&author=P+Kurkcuoglu&author=T+Takmaz&author=C+Gurdal&author=I+Can&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0009"> <div class="reference-title-banner"> <h4 class="title">Ernst 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0010"> <div class="citation-journal">Ernst BJ, García‐Aguirre G, Oliver SC, Olson JL, Mandava N, Quiroz‐Mercado H. <span class="citation-title">Intravitreal bevacizumab versus panretinal photocoagulation for treatment‐naïve proliferative and severe nonproliferative diabetic retinopathy</span>. <span class="citation"> Acta Ophthalmologica </span><span class="pubYear">2012</span>;<span class="volume">90</span>(7):e573‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22405048" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+versus+panretinal+photocoagulation+for+treatment%E2%80%90na%C3%AFve+proliferative+and+severe+nonproliferative+diabetic+retinopathy+&author=BJ+Ernst&author=G+Garc%C3%ADa%E2%80%90Aguirre&author=SC+Oliver&author=JL+Olson&author=N+Mandava&author=H+Quiroz%E2%80%90Mercado&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0012"> <div class="citation-journal">Garcia‐Aguirre G, Reyna‐Castelan E, Torres M, Kon‐Jara V, Quiroz‐Mercado H. <span class="citation-title">Intravitreal bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non‐proliferative diabetic retinopathy: a contralateral eye study</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">2007</span>;<span class="volume">48</span>:ARVO E‐abstract 5041. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+vs.+panretinal+photocoagulation+for+the+treatment+of+proliferative+and+severe+non%E2%80%90proliferative+diabetic+retinopathy:+a+contralateral+eye+study+&author=G+Garcia%E2%80%90Aguirre&author=E+Reyna%E2%80%90Castelan&author=M+Torres&author=V+Kon%E2%80%90Jara&author=H+Quiroz%E2%80%90Mercado&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0011"> <div class="citation-journal">Garcia‐Aguirre G, Reyna‐Castelán E, Torres‐Soriano M, Kon‐Jara V, Quiroz‐Mercado H. <span class="citation-title">Bevacizumab vs. panretinal photocoagulation for the treatment of proliferative and severe non‐proliferative diabetic retinopathy: a contralateral eye study</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">2008</span>;<span class="volume">48</span>:ARVO E‐abstract 2750. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bevacizumab+vs.+panretinal+photocoagulation+for+the+treatment+of+proliferative+and+severe+non%E2%80%90proliferative+diabetic+retinopathy:+a+contralateral+eye+study+&author=G+Garcia%E2%80%90Aguirre&author=E+Reyna%E2%80%90Castel%C3%A1n&author=M+Torres%E2%80%90Soriano&author=V+Kon%E2%80%90Jara&author=H+Quiroz%E2%80%90Mercado&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0010"> <div class="reference-title-banner"> <h4 class="title">Farahvash 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0013"> <div class="citation-journal">Farahvash MS, Majidi AR, Roohipoor R, Ghassemi F. <span class="citation-title">Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage</span>. <span class="citation"> Retina </span><span class="pubYear">2011</span>;<span class="volume">31</span>(7):1254–60. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21499192" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Preoperative+injection+of+intravitreal+bevacizumab+in+dense+diabetic+vitreous+hemorrhage&author=MS+Farahvash&author=AR+Majidi&author=R+Roohipoor&author=F+Ghassemi&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0011"> <div class="reference-title-banner"> <h4 class="title">González 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0017"> <div class="citation-journal">Gonzalez VH, Vann VR. <span class="citation-title">Treatment of proliferative diabetic retinopathy with intravitreal pegaptanib vs. panretinal photocoagulation</span>. <span class="citation"> American Academy of Ophthalmology </span><span class="pubYear">2007</span>:265. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Treatment+of+proliferative+diabetic+retinopathy+with+intravitreal+pegaptanib+vs.+panretinal+photocoagulation+&author=VH+Gonzalez&author=VR+Vann&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0015"> <div class="citation-journal">Gonzalez VH, Vann VR, Banda RM, Giuliari GP, Guel DA. <span class="citation-title">Pegaptanib sodium (Macugen®) versus panretinal photocoagulation (PRP) for the regression of proliferative diabetic retinopathy</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">2007</span>;<span class="volume">48</span>:ARVO E‐abstract 4030. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pegaptanib+sodium+(Macugen%C2%AE)+versus+panretinal+photocoagulation+(PRP)+for+the+regression+of+proliferative+diabetic+retinopathy+&author=VH+Gonzalez&author=VR+Vann&author=RM+Banda&author=GP+Giuliari&author=DA+Guel&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0016"> <div class="citation-journal">Gonzalez VH, Vann VR, Banda‐Gonzales RM. <span class="citation-title">Selective VEGF Inhibition: effectiveness in modifying the progression of proliferative diabetic retinopathy</span>. <span class="citation"> American Academy of Ophthalmology </span><span class="pubYear">2006</span>:279. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Selective+VEGF+Inhibition:+effectiveness+in+modifying+the+progression+of+proliferative+diabetic+retinopathy+&author=VH+Gonzalez&author=VR+Vann&author=RM+Banda%E2%80%90Gonzales&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0014"> <div class="citation-journal">González VH, Giuliari GP, Banda RM, Guel DA. <span class="citation-title">Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">93</span>(11):1474‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19692371" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+injection+of+pegaptanib+sodium+for+proliferative+diabetic+retinopathy&author=VH+Gonz%C3%A1lez&author=GP+Giuliari&author=RM+Banda&author=DA+Guel&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0012"> <div class="reference-title-banner"> <h4 class="title">Mirshahi 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0018"> <div class="citation-journal">Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. <span class="citation-title">Bevacizumab‐augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double‐masked clinical trial</span>. <span class="citation"> European Journal of Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">18</span>(2):263‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18320520" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bevacizumab%E2%80%90augmented+retinal+laser+photocoagulation+in+proliferative+diabetic+retinopathy:+a+randomized+double%E2%80%90masked+clinical+trial+&author=A+Mirshahi&author=R+Roohipoor&author=A+Lashay&author=SF+Mohammadi&author=A+Abdoallahi&author=H+Faghihi&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0013"> <div class="reference-title-banner"> <h4 class="title">Modarres 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0020"> <div class="citation-journal">Modarres M, Nazari H. <span class="citation-title">Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy</span>. <span class="citation"> American Academy of Ophthalmology </span><span class="pubYear">2007</span>:199. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+injection+of+bevacizumab+before+vitrectomy+for+proliferative+diabetic+retinopathy+&author=M+Modarres&author=H+Nazari&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0019"> <div class="citation-journal">Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. <span class="citation-title">Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy</span>. <span class="citation"> European Journal of Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">19</span>(5):848‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19787608" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+injection+of+bevacizumab+before+vitrectomy+for+proliferative+diabetic+retinopathy+&author=M+Modarres&author=H+Nazari&author=KG+Falavarjani&author=M+Naseripour&author=M+Hashemi&author=MM+Parvaresh&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0014"> <div class="reference-title-banner"> <h4 class="title">Preti 2014 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0021"> <div class="citation-journal">Preti RC, Vasquez Ramirez LM, Ribeiro Monteiro ML, Pelayes DE, Takahashi WY. <span class="citation-title">Structural and functional assessment of macula in patients with high‐risk proliferative diabetic retinopathy submitted to panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial</span>. <span class="citation"> Ophthalmologica </span><span class="pubYear">2013</span>;<span class="volume">230</span>(1):1‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23689115" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Structural+and+functional+assessment+of+macula+in+patients+with+high%E2%80%90risk+proliferative+diabetic+retinopathy+submitted+to+panretinal+photocoagulation+and+associated+intravitreal+bevacizumab+injections:+a+comparative,+randomised,+controlled+trial+&author=RC+Preti&author=LM+VasquezRamirez&author=ML+RibeiroMonteiro&author=DE+Pelayes&author=WY+Takahashi&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0022"> <div class="citation-journal">Preti RC, Vazquez L, Ribeiro M, Kehdi M, Pelayes DE, Yukihiko W. <span class="citation-title">Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2014</span>;<span class="volume">97</span>(7):885‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Contrast+sensitivity+evaluation+in+high+risk+proliferative+diabetic+retinopathy+treated+with+panretinal+photocoagulation+associated+or+not+with+intravitreal+bevacizumab+injections:+a+randomised+clinical+trial+&author=RC+Preti&author=L+Vazquez&author=M+Ribeiro&author=M+Kehdi&author=DE+Pelayes&author=W+Yukihiko&publication_year=2014&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0015"> <div class="reference-title-banner"> <h4 class="title">Ramos Filho 2011 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0023"> <div class="citation-journal">Lucena CR, Ramos Filho JA, Messias AM, Silva JA, Almeida FP, Scott IU, et al. <span class="citation-title">Panretinal photocoagulation versus intravitreal injection retreatment pain in high‐risk proliferative diabetic retinopathy</span>. <span class="citation"> Arquivos Brasileiros de Oftalmologia </span><span class="pubYear">2013</span>;<span class="volume">76</span>(1):18‐20. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23812521" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Panretinal+photocoagulation+versus+intravitreal+injection+retreatment+pain+in+high%E2%80%90risk+proliferative+diabetic+retinopathy+&author=CR+Lucena&author=JA+RamosFilho&author=AM+Messias&author=JA+Silva&author=FP+Almeida&author=IU+Scott&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0024"> <div class="citation-journal">Messias A, Ramos Filho JA, Messias K, Almeida FP, Costa RA, Scott IU, et al. <span class="citation-title">Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high‐risk proliferative diabetic retinopathy</span>. <span class="citation"> Documenta Ophthalmologica </span><span class="pubYear">2012</span>;<span class="volume">124</span>(3):225‐36. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22457045" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Electroretinographic+findings+associated+with+panretinal+photocoagulation+(PRP)+versus+PRP+plus+intravitreal+ranibizumab+treatment+for+high%E2%80%90risk+proliferative+diabetic+retinopathy+&author=A+Messias&author=JA+RamosFilho&author=K+Messias&author=FP+Almeida&author=RA+Costa&author=IU+Scott&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> <div class="bibliography-section" id="CD008721-bib-0025"> <div class="citation-journal">Ramos Filho JA, Messias A, Almeida FP, Ribeiro JA, Costa RA, Scott IU, et al. <span class="citation-title">Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high‐risk proliferative diabetic retinopathy</span>. <span class="citation"> Acta Ophthalmologica </span><span class="pubYear">2011</span>;<span class="volume">89</span>(7):e567‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/21726427" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Panretinal+photocoagulation+(PRP)+versus+PRP+plus+intravitreal+ranibizumab+for+high%E2%80%90risk+proliferative+diabetic+retinopathy+&author=JA+RamosFilho&author=A+Messias&author=FP+Almeida&author=JA+Ribeiro&author=RA+Costa&author=IU+Scott&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0016"> <div class="reference-title-banner"> <h4 class="title">Rizzo 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0026"> <div class="citation-journal">Rizzo S, Genovesi‐Ebert F, Bartolo E, Vento A, Miniaci S, Williams G. <span class="citation-title">Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)</span>. <span class="citation"> Graefe's Archive for Clinical and Experimental Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">246</span>(6):837‐42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18286296" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Injection+of+intravitreal+bevacizumab+(Avastin)+as+a+preoperative+adjunct+before+vitrectomy+surgery+in+the+treatment+of+severe+proliferative+diabetic+retinopathy+(PDR)+&author=S+Rizzo&author=F+Genovesi%E2%80%90Ebert&author=E+Bartolo&author=A+Vento&author=S+Miniaci&author=G+Williams&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0017"> <div class="reference-title-banner"> <h4 class="title">Sohn 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0027"> <div class="citation-journal">Sohn EH, He S, Kim LA, Salehi‐Had H, Javaheri M, Spee C, et al. <span class="citation-title">Angiofibrotic response to vascular endothelial growth factor Inhibition in diabetic retinal detachment</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">130</span>(9):1127‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22965588" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiofibrotic+response+to+vascular+endothelial+growth+factor+Inhibition+in+diabetic+retinal+detachment+&author=EH+Sohn&author=S+He&author=LA+Kim&author=H+Salehi%E2%80%90Had&author=M+Javaheri&author=C+Spee&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_includedStudies" id="CD008721-bbs2-0018"> <div class="reference-title-banner"> <h4 class="title">Zaman 2013 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0028"> <div class="citation-journal">Zaman Y, Rehman A, Fattah M. <span class="citation-title">Intravitreal Avastin as an adjunct in patients with proliferative retinopathy undergoing pars plana vitrectomy</span>. <span class="citation"> Pakistan Journal of Medical Sciences </span><span class="pubYear">2013</span>;<span class="volume">29</span>(2):590‐2. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/24353583" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+Avastin+as+an+adjunct+in+patients+with+proliferative+retinopathy+undergoing+pars+plana+vitrectomy+&author=Y+Zaman&author=A+Rehman&author=M+Fattah&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008721-bbs1-0002"> <h3 class="title">References to studies excluded from this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008721-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0004">additional references</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0019"> <div class="reference-title-banner"> <h4 class="title">Arimura 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0029"> <div class="citation-journal">Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, et al. <span class="citation-title">Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">116</span>(5):921‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19410951" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vitreous+mediators+after+intravitreal+bevacizumab+or+triamcinolone+acetonide+in+eyes+with+proliferative+diabetic+retinopathy+&author=N+Arimura&author=H+Otsuka&author=K+Yamakiri&author=Y+Sonoda&author=S+Nakao&author=Y+Noda&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0020"> <div class="reference-title-banner"> <h4 class="title">Fulda 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0030"> <div class="citation-journal">Fulda E, Ariza E, Lopez A, Graue F. <span class="citation-title">Intravitreal bevacizumab and panretinal photocoagulation as combined treatment in proliferative diabetic retinopathy</span>. <span class="citation"> Retina‐Vitreus </span><span class="pubYear">2010</span>;<span class="volume">18</span>(1):52‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+and+panretinal+photocoagulation+as+combined+treatment+in+proliferative+diabetic+retinopathy+&author=E+Fulda&author=E+Ariza&author=A+Lopez&author=F+Graue&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0021"> <div class="reference-title-banner"> <h4 class="title">Genovesi‐Ebert 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0031"> <div class="citation-journal">Genovesi‐Ebert F, Rizzo S, Bartolo E, Miniaci S, Vento A, Palla M, et al. <span class="citation-title">Injection of intravitreal Avastin before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">2007</span>;<span class="volume">48</span>:ARVO E‐abstract 5044. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Injection+of+intravitreal+Avastin+before+vitrectomy+surgery+in+the+treatment+of+severe+proliferative+diabetic+retinopathy+&author=F+Genovesi%E2%80%90Ebert&author=S+Rizzo&author=E+Bartolo&author=S+Miniaci&author=A+Vento&author=M+Palla&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0022"> <div class="reference-title-banner"> <h4 class="title">Gonzalez 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0032"> <div class="citation-journal">Gonzalez VH, Macugen Diabetic Retinopathy Study Group. <span class="citation-title">Pegaptanib in diabetic retinopathy: improvements in diabetic macular edema, retinal neovascularization, and diabetic retinopathy severity</span>. <span class="citation"> American Academy of Ophthalmology </span><span class="pubYear">2006</span>:192. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Pegaptanib+in+diabetic+retinopathy:+improvements+in+diabetic+macular+edema,+retinal+neovascularization,+and+diabetic+retinopathy+severity+&author=VH+Gonzalez&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0023"> <div class="reference-title-banner"> <h4 class="title">Hattori 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0033"> <div class="citation-journal">Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M. <span class="citation-title">Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy</span>. <span class="citation"> Retina </span><span class="pubYear">2010</span>;<span class="volume">30</span>(5):761‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20453802" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Dose+of+intravitreal+bevacizumab+(Avastin)+used+as+preoperative+adjunct+therapy+for+proliferative+diabetic+retinopathy+&author=T+Hattori&author=H+Shimada&author=H+Nakashizuka&author=Y+Mizutani&author=R+Mori&author=M+Yuzawa&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0024"> <div class="reference-title-banner"> <h4 class="title">Huang 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0034"> <div class="citation-journal">Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. <span class="citation-title">Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage</span>. <span class="citation"> Retina </span><span class="pubYear">2009</span>;<span class="volume">29</span>(8):1134‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19672218" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+and+panretinal+photocoagulation+for+proliferative+diabetic+retinopathy+associated+with+vitreous+hemorrhage+&author=YH+Huang&author=PT+Yeh&author=MS+Chen&author=CH+Yang&author=CM+Yang&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0025"> <div class="reference-title-banner"> <h4 class="title">Ip 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0035"> <div class="citation-journal">Ip MS, Domalpally A, Hopkins JH, Wong P, Ehrlich JS. <span class="citation-title">Long‐term effects of ranibizumab on diabetic retinopathy severity and progression</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">130</span>(9):1145‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/22965590" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Long%E2%80%90term+effects+of+ranibizumab+on+diabetic+retinopathy+severity+and+progression&author=MS+Ip&author=A+Domalpally&author=JH+Hopkins&author=P+Wong&author=JS+Ehrlich&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0026"> <div class="reference-title-banner"> <h4 class="title">Jiang 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0036"> <div class="citation-journal">Jiang Y, Liang X, Li X, Tao Y, Wang K. <span class="citation-title">Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy</span>. <span class="citation"> Acta Ophthalmologica </span><span class="pubYear">2009</span>;<span class="volume">87</span>(7):736‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18803622" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Analysis+of+the+clinical+efficacy+of+intravitreal+bevacizumab+in+the+treatment+of+iris+neovascularization+caused+by+proliferative+diabetic+retinopathy+&author=Y+Jiang&author=X+Liang&author=X+Li&author=Y+Tao&author=K+Wang&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0027"> <div class="reference-title-banner"> <h4 class="title">Jorge 2006 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0037"> <div class="citation-journal">Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. <span class="citation-title">Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)</span>. <span class="citation"> Retina </span><span class="pubYear">2006</span>;<span class="volume">26</span>(9):1006‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17151487" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+for+persistent+new+vessels+in+diabetic+retinopathy+(IBEPE+study)+&author=R+Jorge&author=RA+Costa&author=D+Calucci&author=LP+Cintra&author=IU+Scott&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0028"> <div class="reference-title-banner"> <h4 class="title">Lanzagorta‐Aresti 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0038"> <div class="citation-journal">Lanzagorta‐Aresti A, Palacios‐Pozo E, Menezo Rozalen JL, Navea‐Tejerina A. <span class="citation-title">Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study</span>. <span class="citation"> Retina </span><span class="pubYear">2009</span>;<span class="volume">29</span>(4):530‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19357559" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevention+of+vision+loss+after+cataract+surgery+in+diabetic+macular+edema+with+intravitreal+bevacizumab:+a+pilot+study+&author=A+Lanzagorta%E2%80%90Aresti&author=E+Palacios%E2%80%90Pozo&author=JL+MenezoRozalen&author=A+Navea%E2%80%90Tejerina&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0029"> <div class="reference-title-banner"> <h4 class="title">López‐López 2012 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0039"> <div class="citation-journal">López‐López F, Gómez‐Ulla F, Rodriguez‐Cid MJ, Arias L. <span class="citation-title">Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy</span>. <span class="citation"> ISRN Ophthalmology </span><span class="pubYear">2012</span>;<span class="volume">2012</span>:Article ID 267643. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Triamcinolone+and+bevacizumab+as+adjunctive+therapies+to+panretinal+photocoagulation+for+proliferative+diabetic+retinopathy+&author=F+L%C3%B3pez%E2%80%90L%C3%B3pez&author=F+G%C3%B3mez%E2%80%90Ulla&author=MJ+Rodriguez%E2%80%90Cid&author=L+Arias&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0030"> <div class="reference-title-banner"> <h4 class="title">Michaelides 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0040"> <div class="citation-journal">Michaelides M, Kaines A, Hamilton RD, Fraser‐Bell S, Rajendram R, Quhill F, et al. <span class="citation-title">A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12‐month data: report 2</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">117</span>(6):1078‐86. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20416952" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+prospective+randomized+trial+of+intravitreal+bevacizumab+or+laser+therapy+in+the+management+of+diabetic+macular+edema+(BOLT+study)+12%E2%80%90month+data:+report+2+&author=M+Michaelides&author=A+Kaines&author=RD+Hamilton&author=S+Fraser%E2%80%90Bell&author=R+Rajendram&author=F+Quhill&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0031"> <div class="reference-title-banner"> <h4 class="title">Minnella 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0041"> <div class="citation-journal">Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. <span class="citation-title">Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy</span>. <span class="citation"> Acta Opthalmologica </span><span class="pubYear">2008</span>;<span class="volume">86</span>(6):683‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+in+proliferative+diabetic+retinopathy&author=AM+Minnella&author=CM+Savastano&author=L+Ziccardi&author=A+Scupola&author=B+Falsini&author=E+Balestrazzi&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0032"> <div class="reference-title-banner"> <h4 class="title">Scott 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0042"> <div class="citation-journal">Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, et al. <span class="citation-title">Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2008</span>;<span class="volume">28</span>(1):36‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18185135" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Agreement+between+clinician+and+reading+center+gradings+of+diabetic+retinopathy+severity+level+at+baseline+in+a+phase+2+study+of+intravitreal+bevacizumab+for+diabetic+macular+edema+&author=IU+Scott&author=NM+Bressler&author=SB+Bressler&author=DJ+Browning&author=CK+Chan&author=RP+Danis&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0033"> <div class="reference-title-banner"> <h4 class="title">Shin 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0043"> <div class="citation-journal">Shin YW, Lee YJ, Lee BR, Cho HY. <span class="citation-title">Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high‐risk proliferative diabetic retinopathy</span>. <span class="citation"> Korean Journal of Ophthalmology </span><span class="pubYear">2009</span>;<span class="volume">23</span>(4):266‐72. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/20046686" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effects+of+an+intravitreal+bevacizumab+injection+combined+with+panretinal+photocoagulation+on+high%E2%80%90risk+proliferative+diabetic+retinopathy+&author=YW+Shin&author=YJ+Lee&author=BR+Lee&author=HY+Cho&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0034"> <div class="reference-title-banner"> <h4 class="title">Stergiou 2007 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0044"> <div class="citation-journal">Stergiou P, Kokkinou D, Malamos K, Felekidis A, Kailari S. <span class="citation-title">Varying doses of intravitreal bevacizumab (Avastin) for the treatment of proliferative diabetic retinopathy</span>. <span class="citation"> Investigative Ophthalmology and Visual Science </span><span class="pubYear">2007</span>;<span class="volume">48</span>:ARVO E‐abstract 1395. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Varying+doses+of+intravitreal+bevacizumab+(Avastin)+for+the+treatment+of+proliferative+diabetic+retinopathy+&author=P+Stergiou&author=D+Kokkinou&author=K+Malamos&author=A+Felekidis&author=S+Kailari&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0035"> <div class="reference-title-banner"> <h4 class="title">Tonello 2008 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0045"> <div class="citation-journal">Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. <span class="citation-title">Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high‐risk proliferative diabetic retinopathy (IBeHi study)</span>. <span class="citation"> Acta Ophthalmologica </span><span class="pubYear">2008</span>;<span class="volume">86</span>(4):385‐9. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17995982" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Panretinal+photocoagulation+versus+PRP+plus+intravitreal+bevacizumab+for+high%E2%80%90risk+proliferative+diabetic+retinopathy+(IBeHi+study)+&author=M+Tonello&author=RA+Costa&author=FP+Almeida&author=JC+Barbosa&author=IU+Scott&author=R+Jorge&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0036"> <div class="reference-title-banner"> <h4 class="title">Yeh 2009 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0046"> <div class="citation-journal">Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. <span class="citation-title">Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy</span>. <span class="citation"> Retina </span><span class="pubYear">2009</span>;<span class="volume">29</span>(6):768‐74. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/19516117" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Bevacizumab+pretreatment+in+vitrectomy+with+silicone+oil+for+severe+diabetic+retinopathy&author=PT+Yeh&author=CM+Yang&author=YC+Lin&author=MS+Chen&author=CH+Yang&publication_year=2009&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_excludedStudies" id="CD008721-bbs2-0037"> <div class="reference-title-banner"> <h4 class="title">Zhou 2010 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0047"> <div class="citation-journal">Zhou YY, Zhang RJ. <span class="citation-title">Avastin combined with vitreous cavity injection of triamcinolone acetonide in treatment of diabetic retinopathy with macular edema</span>. <span class="citation"> International Journal of Ophthalmology </span><span class="pubYear">2010</span>;<span class="volume">10</span>(3):475‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Avastin+combined+with+vitreous+cavity+injection+of+triamcinolone+acetonide+in+treatment+of+diabetic+retinopathy+with+macular+edema+&author=YY+Zhou&author=RJ+Zhang&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008721-bbs1-0003"> <h3 class="title">References to ongoing studies</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008721-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0004">additional references</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008721-bbs2-0038"> <div class="reference-title-banner"> <h4 class="title">EUCTR2013‐003272‐12‐GB {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0048"> <div class="citation-other">EUCTR2013‐003272‐12‐GB. <span class="citation-title">Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy</span>. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐003272‐12/GB (accessed 2 November 2014). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008721-bbs2-0039"> <div class="reference-title-banner"> <h4 class="title">NCT01854593 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0049"> <div class="citation-other">NCT01854593. <span class="citation-title">Prospective randomized controlled study of intravitreal injection of 0.16 mg bevacizumab one day before surgery for proliferative diabetic retinopathy</span>. clinicaltrials.gov/show/NCT01854593 (accessed 2 November 2014). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008721-bbs2-0040"> <div class="reference-title-banner"> <h4 class="title">NCT01941329 (PROTEUS) {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0050"> <div class="citation-other">NCT01941329. <span class="citation-title">Prospective, randomized, multicentre, open‐label, phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in monotherapy in the treatment of subjects with high risk proliferative diabetic retinopathy (PROTEUS)</span>. clinicaltrials.gov/show/NCT01941329 (accessed 2 November 2014). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008721-bbs2-0041"> <div class="reference-title-banner"> <h4 class="title">NCT01976923 (PACORES) {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0051"> <div class="citation-other">NCT01976923. <span class="citation-title">Pre‐operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: results of the Pan‐American Collaborative Retina Study (PACORES) Group</span>. clinicaltrials.gov/show/NCT01976923 (accessed 2 November 2014). <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_ongoingStudies" id="CD008721-bbs2-0042"> <div class="reference-title-banner"> <h4 class="title">NCT01988246 {published data only} </h4> </div> <div class="bibliography-section" id="CD008721-bib-0052"> <div class="citation-other">NCT01988246. <span class="citation-title">Prevention of macular edema In patients with diabetic retinopathy undergoing cataract surgery</span>. clinicaltrials.gov/show/NCT01988246 (accessed 2 November 2014). <ul class="citation-link-group"> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008721-bbs1-0004"> <h3 class="title">Additional references</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008721-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0005">other published versions</a></li> </ul> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0043"> <div class="reference-title-banner"> <h4 class="title">ADA 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0053"> <div class="citation-journal">Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. <span class="citation-title">Retinopathy in diabetes</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2006</span>;<span class="volume">27 Suppl 1</span>:84‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Retinopathy+in+diabetes&author=DS+Fong&author=L+Aiello&author=TW+Gardner&author=GL+King&author=G+Blankenship&author=JD+Cavallerano&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0044"> <div class="reference-title-banner"> <h4 class="title">Adamis 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0054"> <div class="citation-journal">Adamis AP, Altaweel M, Bressler NM, Cunningham ET, Davis MD, Goldbaum M, et al. <span class="citation-title">Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2006</span>;<span class="volume">113</span>(1):23‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16343627" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Changes+in+retinal+neovascularization+after+pegaptanib+(Macugen)+therapy+in+diabetic+individuals+&author=AP+Adamis&author=M+Altaweel&author=NM+Bressler&author=ET+Cunningham&author=MD+Davis&author=M+Goldbaum&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0045"> <div class="reference-title-banner"> <h4 class="title">Arevalo 2007</h4> </div> <div class="bibliography-section" id="CD008721-bib-0055"> <div class="citation-journal">Arevalo JF, Fromow‐Guerra J, Quiroz‐Mercado H, Sanchez JG, Wu L, Maia M, et al. <span class="citation-title">Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan‐American Collaborative Retina Study Group at 6‐month follow‐up</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2007</span>;<span class="volume">114</span>(4):743‐50. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17398322" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Primary+intravitreal+bevacizumab+(Avastin)+for+diabetic+macular+edema:+results+from+the+Pan%E2%80%90American+Collaborative+Retina+Study+Group+at+6%E2%80%90month+follow%E2%80%90up+&author=JF+Arevalo&author=J+Fromow%E2%80%90Guerra&author=H+Quiroz%E2%80%90Mercado&author=JG+Sanchez&author=L+Wu&author=M+Maia&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0046"> <div class="reference-title-banner"> <h4 class="title">Avery 2006a</h4> </div> <div class="bibliography-section" id="CD008721-bib-0056"> <div class="citation-journal">Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. <span class="citation-title">Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2006</span>;<span class="volume">113</span>(10):1695.e1‐15. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+in+the+treatment+of+proliferative+diabetic+retinopathy&author=RL+Avery&author=J+Pearlman&author=DJ+Pieramici&author=MD+Rabena&author=AA+Castellarin&author=MA+Nasir&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0047"> <div class="reference-title-banner"> <h4 class="title">Avery 2006b</h4> </div> <div class="bibliography-section" id="CD008721-bib-0057"> <div class="citation-journal">Avery RL. <span class="citation-title">Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment</span>. <span class="citation"> Retina </span><span class="pubYear">2006</span>;<span class="volume">26</span>(3):352‐4. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16508438" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Regression+of+retinal+and+iris+neovascularization+after+intravitreal+bevacizumab+(Avastin)+treatment+&author=RL+Avery&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0048"> <div class="reference-title-banner"> <h4 class="title">Bussolati 2001</h4> </div> <div class="bibliography-section" id="CD008721-bib-0058"> <div class="citation-journal">Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. <span class="citation-title">Vascular endothelial growth factor receptor‐1 modulates vascular endothelial growth factor‐mediated angiogenesis via nitric oxide</span>. <span class="citation"> American Journal of Pathology </span><span class="pubYear">2001</span>;<span class="volume">159</span>(3):993‐1008. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11549592" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vascular+endothelial+growth+factor+receptor%E2%80%901+modulates+vascular+endothelial+growth+factor%E2%80%90mediated+angiogenesis+via+nitric+oxide+&author=B+Bussolati&author=C+Dunk&author=M+Grohman&author=CD+Kontos&author=J+Mason&author=A+Ahmed&publication_year=2001&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0049"> <div class="reference-title-banner"> <h4 class="title">Carmeliet 2004</h4> </div> <div class="bibliography-section" id="CD008721-bib-0059"> <div class="citation-journal">Carmeliet P. <span class="citation-title">Manipulating angiogenesis in medicine</span>. <span class="citation"> Journal of Internal Medicine </span><span class="pubYear">2004</span>;<span class="volume">255</span>(5):538‐61. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15078497" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Manipulating+angiogenesis+in+medicine&author=P+Carmeliet&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0050"> <div class="reference-title-banner"> <h4 class="title">Chen 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0060"> <div class="citation-journal">Chen E, Park CH. <span class="citation-title">Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy</span>. <span class="citation"> Retina </span><span class="pubYear">2006</span>;<span class="volume">26</span>(6):699‐700. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16829817" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Use+of+intravitreal+bevacizumab+as+a+preoperative+adjunct+for+tractional+retinal+detachment+repair+in+severe+proliferative+diabetic+retinopathy+&author=E+Chen&author=CH+Park&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0051"> <div class="reference-title-banner"> <h4 class="title">Chew 1996</h4> </div> <div class="bibliography-section" id="CD008721-bib-0061"> <div class="citation-journal">Chew EY, Klein ML, Ferris FL, Remaley NA, Murphy RP, Chantry K, et al. <span class="citation-title">Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1996</span>;<span class="volume">114</span>(9):1079‐84. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8790092" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Association+of+elevated+serum+lipid+levels+with+retinal+hard+exudate+in+diabetic+retinopathy.+Early+Treatment+Diabetic+Retinopathy+Study+(ETDRS)+Report+22+&author=EY+Chew&author=ML+Klein&author=FL+Ferris&author=NA+Remaley&author=RP+Murphy&author=K+Chantry&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0052"> <div class="reference-title-banner"> <h4 class="title">Chun 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0062"> <div class="citation-journal">Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. <span class="citation-title">A pilot study of multiple intravitreal injections of ranibizumab in patients with center‐involving clinically significant diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2006</span>;<span class="volume">113</span>(10):1706‐12. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17011952" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+pilot+study+of+multiple+intravitreal+injections+of+ranibizumab+in+patients+with+center%E2%80%90involving+clinically+significant+diabetic+macular+edema+&author=DW+Chun&author=JS+Heier&author=TM+Topping&author=JS+Duker&author=JM+Bankert&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0053"> <div class="reference-title-banner"> <h4 class="title">Cunningham 2005</h4> </div> <div class="bibliography-section" id="CD008721-bib-0063"> <div class="citation-journal">Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. <span class="citation-title">A phase II randomized double‐masked trial of pegaptanib, an anti‐vascular endothelial growth factor aptamer, for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2005</span>;<span class="volume">112</span>(10):1747‐57. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16154196" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+II+randomized+double%E2%80%90masked+trial+of+pegaptanib,+an+anti%E2%80%90vascular+endothelial+growth+factor+aptamer,+for+diabetic+macular+edema+&author=ET+Cunningham&author=AP+Adamis&author=M+Altaweel&author=LP+Aiello&author=NM+Bressler&author=DJ+D'Amico&publication_year=2005&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0054"> <div class="reference-title-banner"> <h4 class="title">Davis 1998</h4> </div> <div class="bibliography-section" id="CD008721-bib-0064"> <div class="citation-journal">Davis MD, Fisher MR, Gagnon RE. <span class="citation-title">Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18</span>. <span class="citation"> Investigative Ophthalmology &amp; Visual Science </span><span class="pubYear">1998</span>;<span class="volume">39</span>(2):233‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9477980" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+high%E2%80%90risk+proliferative+diabetic+retinopathy+and+severe+visual+loss:+Early+Treatment+Diabetic+Retinopathy+Study+report+#18+&author=MD+Davis&author=MR+Fisher&author=RE+Gagnon&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0055"> <div class="reference-title-banner"> <h4 class="title">DerSimonian 1986</h4> </div> <div class="bibliography-section" id="CD008721-bib-0065"> <div class="citation-journal">DerSimonian R, Laird N. <span class="citation-title">Meta‐analysis in clinical trials</span>. <span class="citation"> Controlled Clinical Trials </span><span class="pubYear">1986</span>;<span class="volume">7</span>(3):177‐88. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3802833" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Meta%E2%80%90analysis+in+clinical+trials&author=R+DerSimonian&author=N+Laird&publication_year=1986&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0056"> <div class="reference-title-banner"> <h4 class="title">DRSRG 1978</h4> </div> <div class="bibliography-section" id="CD008721-bib-0066"> <div class="citation-journal">Anonymous. <span class="citation-title">Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1978</span>;<span class="volume">85</span>(1):82‐106. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/345173" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Photocoagulation+treatment+of+proliferative+diabetic+retinopathy:+the+second+report+of+Diabetic+Retinopathy+Study+findings+&author=+Anonymous&publication_year=1978&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0057"> <div class="reference-title-banner"> <h4 class="title">DRSRG 1981a</h4> </div> <div class="bibliography-section" id="CD008721-bib-0067"> <div class="citation-journal">Anonymous. <span class="citation-title">Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic Retinopathy Study report no. 5</span>. <span class="citation"> Developments in Ophthalmology </span><span class="pubYear">1981</span>;<span class="volume">2</span>:248‐56. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7262408" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Photocoagulation+treatment+of+proliferative+diabetic+retinopathy:+relationship+of+adverse+treatment+effects+to+retinopathy+severity.+Diabetic+Retinopathy+Study+report+no.+5+&author=+Anonymous&publication_year=1981&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0058"> <div class="reference-title-banner"> <h4 class="title">DRSRG 1981b</h4> </div> <div class="bibliography-section" id="CD008721-bib-0068"> <div class="citation-journal">Anonymous. <span class="citation-title">Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. The Diabetic Retinopathy Study Research Group</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1981</span>;<span class="volume">88</span>(7):583‐600. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7196564" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Photocoagulation+treatment+of+proliferative+diabetic+retinopathy.+Clinical+application+of+Diabetic+Retinopathy+Study+(DRS)+findings,+DRS+report+number+8.+The+Diabetic+Retinopathy+Study+Research+Group+&author=+Anonymous&publication_year=1981&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0059"> <div class="reference-title-banner"> <h4 class="title">DRVSRG 1985</h4> </div> <div class="bibliography-section" id="CD008721-bib-0069"> <div class="citation-journal">Anonymous. <span class="citation-title">Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two‐year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1985</span>;<span class="volume">103</span>(11):1644‐52. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2865943" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Early+vitrectomy+for+severe+vitreous+hemorrhage+in+diabetic+retinopathy.+Two%E2%80%90year+results+of+a+randomized+trial.+Diabetic+Retinopathy+Vitrectomy+Study+report+2.+The+Diabetic+Retinopathy+Vitrectomy+Study+Research+Group+&author=+Anonymous&publication_year=1985&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0060"> <div class="reference-title-banner"> <h4 class="title">ETDRSRG 1985</h4> </div> <div class="bibliography-section" id="CD008721-bib-0070"> <div class="citation-journal">Anonymous. <span class="citation-title">Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1985</span>;<span class="volume">103</span>(12):1796‐806. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2866759" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Photocoagulation+for+diabetic+macular+edema.+Early+Treatment+Diabetic+Retinopathy+Study+report+number+1.+Early+Treatment+Diabetic+Retinopathy+Study+research+group+&author=+Anonymous&publication_year=1985&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0061"> <div class="reference-title-banner"> <h4 class="title">ETDRSRG 1991a</h4> </div> <div class="bibliography-section" id="CD008721-bib-0071"> <div class="citation-journal">Anonymous. <span class="citation-title">Grading diabetic retinopathy from stereoscopic color fundus photographs‐‐an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98 Suppl</span>(5):786‐806. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Grading+diabetic+retinopathy+from+stereoscopic+color+fundus+photographs%E2%80%90%E2%80%90an+extension+of+the+modified+Airlie+House+classification.+ETDRS+report+number+10.+Early+Treatment+Diabetic+Retinopathy+Study+Research+Group+&author=+Anonymous&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0062"> <div class="reference-title-banner"> <h4 class="title">ETDRSRG 1991b</h4> </div> <div class="bibliography-section" id="CD008721-bib-0072"> <div class="citation-journal">Anonymous. <span class="citation-title">Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98 Suppl</span>(5):823‐33. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fundus+photographic+risk+factors+for+progression+of+diabetic+retinopathy.+ETDRS+report+number+12.+Early+Treatment+Diabetic+Retinopathy+Study+Research+Group+&author=+Anonymous&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0063"> <div class="reference-title-banner"> <h4 class="title">ETDRSRG 1991c</h4> </div> <div class="bibliography-section" id="CD008721-bib-0073"> <div class="citation-journal">Anonymous. <span class="citation-title">Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1991</span>;<span class="volume">98 Suppl</span>(5):766‐85. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Early+photocoagulation+for+diabetic+retinopathy.+ETDRS+report+number+9.+Early+Treatment+Diabetic+Retinopathy+Study+Research+Group+&author=+Anonymous&publication_year=1991&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0064"> <div class="reference-title-banner"> <h4 class="title">Ferris 1982</h4> </div> <div class="bibliography-section" id="CD008721-bib-0074"> <div class="citation-journal">Ferris FL, Kassoff A, Bresnick GH, Bailey I. <span class="citation-title">New visual acuity charts for clinical research</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">1982</span>;<span class="volume">94</span>(1):91‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7091289" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=New+visual+acuity+charts+for+clinical+research&author=FL+Ferris&author=A+Kassoff&author=GH+Bresnick&author=I+Bailey&publication_year=1982&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0065"> <div class="reference-title-banner"> <h4 class="title">Gilbert 2000</h4> </div> <div class="bibliography-section" id="CD008721-bib-0075"> <div class="citation-journal">Gilbert R, Kelly D, Cox A. <span class="citation-title">Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes</span>. <span class="citation"> Diabetologia </span><span class="pubYear">2000</span>;<span class="volume">43</span>(11):1360‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11126403" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Angiotensin+converting+enzyme+inhibition+reduces+retinal+overexpression+of+vascular+endothelial+growth+factor+and+hyperpermeability+in+experimental+diabetes+&author=R+Gilbert&author=D+Kelly&author=A+Cox&publication_year=2000&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0066"> <div class="reference-title-banner"> <h4 class="title">Glanville 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0076"> <div class="citation-journal">Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. <span class="citation-title">How to identify randomized controlled trials in MEDLINE: ten years on</span>. <span class="citation"> Journal of the Medical Library Association </span><span class="pubYear">2006</span>;<span class="volume">94</span>(2):130‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16636704" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=How+to+identify+randomized+controlled+trials+in+MEDLINE:+ten+years+on&author=JM+Glanville&author=C+Lefebvre&author=JN+Miles&author=J+Camosso%E2%80%90Stefinovic&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0067"> <div class="reference-title-banner"> <h4 class="title">GRADEpro 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD008721-bib-0077"> <div class="citation-other">McMaster University. <span class="citation-title">GRADEpro</span>. Version 15 April 2014. McMaster University, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0068"> <div class="reference-title-banner"> <h4 class="title">Haritoglou 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0078"> <div class="citation-journal">Haritoglou C, Kook D, Neibauer A, Wolf A, Priglinger S, Strauss R, et al. <span class="citation-title">Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema</span>. <span class="citation"> Retina </span><span class="pubYear">2006</span>;<span class="volume">26</span>(9):999‐1005. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17151486" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+therapy+for+persistent+diffuse+diabetic+macular+edema+&author=C+Haritoglou&author=D+Kook&author=A+Neibauer&author=A+Wolf&author=S+Priglinger&author=R+Strauss&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0069"> <div class="reference-title-banner"> <h4 class="title">Hayward 2002</h4> </div> <div class="bibliography-section" id="CD008721-bib-0079"> <div class="citation-journal">Hayward LM, Burden ML, Burden AC, Blackledge H, Raymond NT, Botha JL, et al. <span class="citation-title">What is the prevalence of visual impairment in the general and diabetic populations: are there ethnic and gender differences?</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>(1):27‐3. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11869300" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=What+is+the+prevalence+of+visual+impairment+in+the+general+and+diabetic+populations:+are+there+ethnic+and+gender+differences?+&author=LM+Hayward&author=ML+Burden&author=AC+Burden&author=H+Blackledge&author=NT+Raymond&author=JL+Botha&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0070"> <div class="reference-title-banner"> <h4 class="title">Higgins 2011</h4> </div> <div class="bibliography-section" id="CD008721-bib-0080"> <div class="citation-other">Higgins JPT, Green S. <span class="citation-title">Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0071"> <div class="reference-title-banner"> <h4 class="title">Jaffe 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0081"> <div class="citation-journal">Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T, et al. <span class="citation-title">Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty‐four‐week results of a multicenter randomized clinical study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2006</span>;<span class="volume">113</span>(6):1020‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16690128" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Fluocinolone+acetonide+implant+(Retisert)+for+noninfectious+posterior+uveitis:+thirty%E2%80%90four%E2%80%90week+results+of+a+multicenter+randomized+clinical+study+&author=GJ+Jaffe&author=D+Martin&author=D+Callanan&author=PA+Pearson&author=B+Levy&author=T+Comstock&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0072"> <div class="reference-title-banner"> <h4 class="title">Klein 1984</h4> </div> <div class="bibliography-section" id="CD008721-bib-0082"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">1984</span>;<span class="volume">102</span>(4):520‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/6367724" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+Wisconsin+epidemiologic+study+of+diabetic+retinopathy.+II.+Prevalence+and+risk+of+diabetic+retinopathy+when+age+at+diagnosis+is+less+than+30+years+&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1984&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0073"> <div class="reference-title-banner"> <h4 class="title">Klein 1988</h4> </div> <div class="bibliography-section" id="CD008721-bib-0083"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy</span>. <span class="citation"> JAMA </span><span class="pubYear">1988</span>;<span class="volume">260</span>(19):2864‐71. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/3184351" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Glycosylated+hemoglobin+predicts+the+incidence+and+progression+of+diabetic+retinopathy&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1988&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0074"> <div class="reference-title-banner"> <h4 class="title">Klein 1989</h4> </div> <div class="bibliography-section" id="CD008721-bib-0084"> <div class="citation-journal">Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. <span class="citation-title">Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?</span>. <span class="citation"> Archives of Internal Medicine </span><span class="pubYear">1989</span>;<span class="volume">149</span>(11):2427‐32. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2684072" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Is+blood+pressure+a+predictor+of+the+incidence+or+progression+of+diabetic+retinopathy?&author=R+Klein&author=BE+Klein&author=SE+Moss&author=MD+Davis&author=DL+DeMets&publication_year=1989&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0075"> <div class="reference-title-banner"> <h4 class="title">Klein 1990</h4> </div> <div class="bibliography-section" id="CD008721-bib-0085"> <div class="citation-journal">Klein BE, Moss SE, Klein R. <span class="citation-title">Effect of pregnancy on progression of diabetic retinopathy</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">1990</span>;<span class="volume">13</span>(1):34‐40. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/2404715" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Effect+of+pregnancy+on+progression+of+diabetic+retinopathy&author=BE+Klein&author=SE+Moss&author=R+Klein&publication_year=1990&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0076"> <div class="reference-title-banner"> <h4 class="title">Klein 2002a</h4> </div> <div class="bibliography-section" id="CD008721-bib-0086"> <div class="citation-journal">Klein R, Klein BE. <span class="citation-title">Blood pressure control and diabetic retinopathy</span>. <span class="citation"> British Journal of Ophthalmology </span><span class="pubYear">2002</span>;<span class="volume">86</span>(4):365‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11914198" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure+control+and+diabetic+retinopathy&author=R+Klein&author=BE+Klein&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0077"> <div class="reference-title-banner"> <h4 class="title">Klein 2002b</h4> </div> <div class="bibliography-section" id="CD008721-bib-0087"> <div class="citation-journal">Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, et al. <span class="citation-title">The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2002</span>;<span class="volume">109</span>(7):1225‐34. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12093643" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+association+of+atherosclerosis,+vascular+risk+factors,+and+retinopathy+in+adults+with+diabetes:+the+atherosclerosis+risk+in+communities+study+&author=R+Klein&author=AR+Sharrett&author=BE+Klein&author=SE+Moss&author=AR+Folsom&author=TY+Wong&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0078"> <div class="reference-title-banner"> <h4 class="title">Kullberg 2002</h4> </div> <div class="bibliography-section" id="CD008721-bib-0088"> <div class="citation-journal">Kullberg CE, Abrahamsson M, Arnqvist HJ, Finnstrom K, Ludvigsson J. VISS Study Group. <span class="citation-title">Prevalence of retinopathy differs with age at onset of diabetes in a population of patients with Type 1 diabetes</span>. <span class="citation"> Diabetes Medicine </span><span class="pubYear">2002</span>;<span class="volume">19</span>(11):924‐31. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Prevalence+of+retinopathy+differs+with+age+at+onset+of+diabetes+in+a+population+of+patients+with+Type+1+diabetes+&author=CE+Kullberg&author=M+Abrahamsson&author=HJ+Arnqvist&author=K+Finnstrom&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0079"> <div class="reference-title-banner"> <h4 class="title">Martidis 2002</h4> </div> <div class="bibliography-section" id="CD008721-bib-0089"> <div class="citation-journal">Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. <span class="citation-title">Intravitreal triamcinolone for refractory diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2002</span>;<span class="volume">109</span>(5):920‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/11986098" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+triamcinolone+for+refractory+diabetic+macular+edema&author=A+Martidis&author=JS+Duker&author=PB+Greenberg&author=AH+Rogers&author=CA+Puliafito&author=E+Reichel&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0080"> <div class="reference-title-banner"> <h4 class="title">Mason 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0090"> <div class="citation-journal">Mason JO, Nixon PA, White MF. <span class="citation-title">Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">2006</span>;<span class="volume">142</span>(4):685‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17011869" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+injection+of+bevacizumab+(Avastin)+as+adjunctive+treatment+of+proliferative+diabetic+retinopathy+&author=JO+Mason&author=PA+Nixon&author=MF+White&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0081"> <div class="reference-title-banner"> <h4 class="title">Mathiesen 1995</h4> </div> <div class="bibliography-section" id="CD008721-bib-0091"> <div class="citation-journal">Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. <span class="citation-title">The natural course of microalbuminuria in insulin‐dependent diabetes: a 10‐year prospective study</span>. <span class="citation"> Diabetic Medicine </span><span class="pubYear">1995</span>;<span class="volume">12</span>(6):482‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/7648820" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=The+natural+course+of+microalbuminuria+in+insulin%E2%80%90dependent+diabetes:+a+10%E2%80%90year+prospective+study+&author=ER+Mathiesen&author=B+Ronn&author=B+Storm&author=H+Foght&author=T+Deckert&publication_year=1995&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0082"> <div class="reference-title-banner"> <h4 class="title">Moss 1994</h4> </div> <div class="bibliography-section" id="CD008721-bib-0092"> <div class="citation-journal">Moss SE, Klein R, Klein B. <span class="citation-title">Ten‐years incidence of visual loss in a diabetic population</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1994</span>;<span class="volume">101</span>(6):1061‐70. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8008348" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Ten%E2%80%90years+incidence+of+visual+loss+in+a+diabetic+population&author=SE+Moss&author=R+Klein&author=B+Klein&publication_year=1994&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0083"> <div class="reference-title-banner"> <h4 class="title">Moss 1996</h4> </div> <div class="bibliography-section" id="CD008721-bib-0093"> <div class="citation-journal">Moss S, Klein R, Klein BE. <span class="citation-title">Cigarette smoking and ten‐year progression in diabetic retinopathy</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">1996</span>;<span class="volume">103</span>(9):1438‐42. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/8841303" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cigarette+smoking+and+ten%E2%80%90year+progression+in+diabetic+retinopathy&author=S+Moss&author=R+Klein&author=BE+Klein&publication_year=1996&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0084"> <div class="reference-title-banner"> <h4 class="title">Nauck 1997</h4> </div> <div class="bibliography-section" id="CD008721-bib-0094"> <div class="citation-journal">Nauck M, Roth M, Tamm M, Eickleberg O, Weiland H, Stulz P, et al. <span class="citation-title">Induction of vascular endothelial growth factor by platelet‐activating factor and platelet‐derived growth factor is downregulated by corticosteroids</span>. <span class="citation"> American Journal of Respiratory Cell and Molecular Biology </span><span class="pubYear">1997</span>;<span class="volume">16</span>(4):398‐406. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9115750" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Induction+of+vascular+endothelial+growth+factor+by+platelet%E2%80%90activating+factor+and+platelet%E2%80%90derived+growth+factor+is+downregulated+by+corticosteroids+&author=M+Nauck&author=M+Roth&author=M+Tamm&author=O+Eickleberg&author=H+Weiland&author=P+Stulz&publication_year=1997&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0085"> <div class="reference-title-banner"> <h4 class="title">Resnikoff 2004</h4> </div> <div class="bibliography-section" id="CD008721-bib-0095"> <div class="citation-journal">Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. <span class="citation-title">Global data on visual impairment in the year 2002</span>. <span class="citation"> Bulletin of the World Health Organization </span><span class="pubYear">2004</span>;<span class="volume">82</span>(11):844‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/15640920" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Global+data+on+visual+impairment+in+the+year+2002&author=S+Resnikoff&author=D+Pascolini&author=D+Etya'ale&author=I+Kocur&author=R+Pararajasegaram&author=GP+Pokharel&publication_year=2004&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0086"> <div class="reference-title-banner"> <h4 class="title">RevMan 2014 [Computer program]</h4> </div> <div class="bibliography-section" id="CD008721-bib-0096"> <div class="citation-other">The Nordic Cochrane Centre, The Cochrane Collaboration. <span class="citation-title">Review Manager (RevMan)</span>. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, <span class="pubYear">2014</span>. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0087"> <div class="reference-title-banner"> <h4 class="title">Scott 2007</h4> </div> <div class="bibliography-section" id="CD008721-bib-0097"> <div class="citation-journal">Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al. Diabetic Retinopathy Clinical Research Network. <span class="citation-title">A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2007</span>;<span class="volume">114</span>(10):1860‐67. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17698196" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=A+phase+II+randomized+clinical+trial+of+intravitreal+bevacizumab+for+diabetic+macular+edema+&author=IU+Scott&author=AR+Edwards&author=RW+Beck&author=NM+Bressler&author=CK+Chan&author=MJ+Elman&publication_year=2007&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0088"> <div class="reference-title-banner"> <h4 class="title">Sennlaub 2003</h4> </div> <div class="bibliography-section" id="CD008721-bib-0098"> <div class="citation-journal">Sennlaub F, Valamanesh F, Vazquez‐Tello A, El‐Asrar AM, Checchin D, Brault S, et al. <span class="citation-title">Cyclooxygenase‐2 in human and experimental ischemic proliferative retinopathy</span>. <span class="citation"> Circulation </span><span class="pubYear">2003</span>;<span class="volume">108</span>(2):198‐204. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12821538" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Cyclooxygenase%E2%80%902+in+human+and+experimental+ischemic+proliferative+retinopathy&author=F+Sennlaub&author=F+Valamanesh&author=A+Vazquez%E2%80%90Tello&author=AM+El%E2%80%90Asrar&author=D+Checchin&author=S+Brault&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0089"> <div class="reference-title-banner"> <h4 class="title">Shima 2008</h4> </div> <div class="bibliography-section" id="CD008721-bib-0099"> <div class="citation-journal">Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. <span class="citation-title">Complications in patients after intravitreal injection of bevacizumab</span>. <span class="citation"> Acta Ophthalmologica </span><span class="pubYear">2008</span>;<span class="volume">86</span>(4):372‐6. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/18028234" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Complications+in+patients+after+intravitreal+injection+of+bevacizumab&author=C+Shima&author=H+Sakaguchi&author=F+Gomi&author=M+Kamei&author=Y+Ikuno&author=Y+Oshima&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0090"> <div class="reference-title-banner"> <h4 class="title">Smith 2011</h4> </div> <div class="bibliography-section" id="CD008721-bib-0100"> <div class="citation-journal">Smith JM, Steel DHW. <span class="citation-title">Anti‐vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2011</span>, Issue 5. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD008214.pub2" target="_blank"><span>10.1002/14651858.CD008214.pub2</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+prevention+of+postoperative+vitreous+cavity+haemorrhage+after+vitrectomy+for+proliferative+diabetic+retinopathy+&author=JM+Smith&author=DHW+Steel&publication_year=2011&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0091"> <div class="reference-title-banner"> <h4 class="title">Spaide 2006</h4> </div> <div class="bibliography-section" id="CD008721-bib-0101"> <div class="citation-journal">Spaide RF, Fisher YL. <span class="citation-title">Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage</span>. <span class="citation"> Retina </span><span class="pubYear">2006</span>;<span class="volume">26</span>(3):275‐8. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/16508426" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intravitreal+bevacizumab+(Avastin)+treatment+of+proliferative+diabetic+retinopathy+complicated+by+vitreous+hemorrhage+&author=RF+Spaide&author=YL+Fisher&publication_year=2006&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0092"> <div class="reference-title-banner"> <h4 class="title">Sterne 2011</h4> </div> <div class="bibliography-section" id="CD008721-bib-0102"> <div class="citation-other">Sterne JAC, Egger M, Moher D. <span class="citation-title">Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</span>. Available from www.cochrane‐handbook.org. <ul class="citation-link-group"> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0093"> <div class="reference-title-banner"> <h4 class="title">UKPDSG 1998a</h4> </div> <div class="bibliography-section" id="CD008721-bib-0103"> <div class="citation-journal">Anonymous. <span class="citation-title">Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group</span>. <span class="citation"> Lancet </span><span class="pubYear">1998</span>;<span class="volume">352</span>(9131):837‐53. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9742976" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Intensive+blood%E2%80%90glucose+control+with+sulphonylureas+or+insulin+compared+with+conventional+treatment+and+risk+of+complications+in+patients+with+type+2+diabetes+(UKPDS+33).+UK+Prospective+Diabetes+Study+(UKPDS)+Group+&author=+Anonymous&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0094"> <div class="reference-title-banner"> <h4 class="title">UKPDSG 1998b</h4> </div> <div class="bibliography-section" id="CD008721-bib-0104"> <div class="citation-journal">Anonymous. <span class="citation-title">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group</span>. <span class="citation"> BMJ </span><span class="pubYear">1998</span>;<span class="volume">317</span>(7160):703‐13. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/9732337" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Tight+blood+pressure+control+and+risk+of+macrovascular+and+microvascular+complications+in+type+2+diabetes:+UKPDS+38.+UK+Prospective+Diabetes+Study+Group+&author=+Anonymous&publication_year=1998&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0095"> <div class="reference-title-banner"> <h4 class="title">Van Leiden 2002</h4> </div> <div class="bibliography-section" id="CD008721-bib-0105"> <div class="citation-journal">Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. <span class="citation-title">Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study</span>. <span class="citation"> Diabetes Care </span><span class="pubYear">2002</span>;<span class="volume">25</span>(8):1320‐5. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12145228" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Blood+pressure,+lipids,+and+obesity+are+associated+with+retinopathy:+the+Hoorn+study&author=HA+Leiden&author=JM+Dekker&author=AC+Moll&author=G+Nijpels&author=RJ+Heine&author=LM+Bouter&publication_year=2002&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0096"> <div class="reference-title-banner"> <h4 class="title">Van Leiden 2003</h4> </div> <div class="bibliography-section" id="CD008721-bib-0106"> <div class="citation-journal">Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. <span class="citation-title">Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study</span>. <span class="citation"> Archives of Ophthalmology </span><span class="pubYear">2003</span>;<span class="volume">121</span>(2):245‐51. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/12583792" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Risk+factors+for+incident+retinopathy+in+a+diabetic+and+nondiabetic+population:+the+Hoorn+study+&author=HA+Leiden&author=JM+Dekker&author=AC+Moll&author=G+Nijpels&author=RJ+Heine&author=LM+Bouter&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0097"> <div class="reference-title-banner"> <h4 class="title">Virgili 2012</h4> </div> <div class="bibliography-section" id="CD008721-bib-0107"> <div class="citation-journal">Virgili G, Parravano M, Menchini F, Brunetti M. <span class="citation-title">Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2012</span>, Issue 12. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD007419.pub3" target="_blank"><span>10.1002/14651858.CD007419.pub3</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23235642" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Antiangiogenic+therapy+with+anti%E2%80%90vascular+endothelial+growth+factor+modalities+for+diabetic+macular+oedema+&author=G+Virgili&author=M+Parravano&author=F+Menchini&author=M+Brunetti&publication_year=2012&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0098"> <div class="reference-title-banner"> <h4 class="title">Wilkinson 2003</h4> </div> <div class="bibliography-section" id="CD008721-bib-0108"> <div class="citation-journal">Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. <span class="citation-title">Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales</span>. <span class="citation"> Ophthalmology </span><span class="pubYear">2003</span>;<span class="volume">110</span>(9):1677‐82. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/13129861" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Proposed+international+clinical+diabetic+retinopathy+and+diabetic+macular+edema+disease+severity+scales+&author=CP+Wilkinson&author=FL+Ferris&author=RE+Klein&author=PP+Lee&author=CD+Agardh&author=M+Davis&publication_year=2003&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0099"> <div class="reference-title-banner"> <h4 class="title">Wu 2008</h4> </div> <div class="bibliography-section" id="CD008721-bib-0109"> <div class="citation-journal">Wu L, Martínez‐Castellanos MA, Quiroz‐Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. <span class="citation-title">Twelve‐month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan‐American Collaborative Retina Study Group (PACORES)</span>. <span class="citation"> Graefe's Archive for Clinical and Experimental Ophthalmology </span><span class="pubYear">2008</span>;<span class="volume">246</span>(1):81‐7. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/17674014" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Twelve%E2%80%90month+safety+of+intravitreal+injections+of+bevacizumab+(Avastin):+results+of+the+Pan%E2%80%90American+Collaborative+Retina+Study+Group+(PACORES)+&author=L+Wu&author=MA+Mart%C3%ADnez%E2%80%90Castellanos&author=H+Quiroz%E2%80%90Mercado&author=JF+Arevalo&author=MH+Berrocal&author=ME+Farah&publication_year=2008&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> <div class="bibliographies references_additionalReferences" id="CD008721-bbs2-0100"> <div class="reference-title-banner"> <h4 class="title">Zhang 2013</h4> </div> <div class="bibliography-section" id="CD008721-bib-0110"> <div class="citation-journal">Zhang ZH, Liu HY, Hernandez‐Da Mota SE, Romano MR, Falavarjani KG, Ahmadieh H, et al. <span class="citation-title">Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta‐analysis of randomized controlled trials</span>. <span class="citation"> American Journal of Ophthalmology </span><span class="pubYear">2013</span>;<span class="volume">156</span>(1):106‐15. <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUPMNSGTLUPNSXT65UJNAYGP55X/pubmed/23791371" target="_blank"> <span>PubMed</span> </a> </li> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Vitrectomy+with+or+without+preoperative+intravitreal+bevacizumab+for+proliferative+diabetic+retinopathy:+a+meta%E2%80%90analysis+of+randomized+controlled+trials+&author=ZH+Zhang&author=HY+Liu&author=SE+Hernandez%E2%80%90DaMota&author=MR+Romano&author=KG+Falavarjani&author=H+Ahmadieh&publication_year=2013&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> <section> <div class="section-header" id="CD008721-bbs1-0005"> <h3 class="title">References to other published versions of this review</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a class="jump-to" href="#CD008721-bbs1-0001">included studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0002">excluded studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0003">ongoing studies</a></li> <li><a class="jump-to" href="#CD008721-bbs1-0004">additional references</a></li> </ul> </div> </div> <div class="bibliographies references_otherVersions" id="CD008721-bbs2-0101"> <div class="reference-title-banner"> <h4 class="title">Martinez‐Zapata 2010</h4> </div> <div class="bibliography-section" id="CD008721-bib-0111"> <div class="citation-journal">Martinez‐Zapata MJ, Martí‐Carvajal AJ, Solà I, Pijoán JI, Buil‐Calvo JA. <span class="citation-title">Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy (Protocol)</span>. <span class="citation"> Cochrane Database of Systematic Reviews </span><span class="pubYear">2010</span>, Issue 9. [DOI: <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MS6C63DQNEYG86UH/10.1002/14651858.CD008721" target="_blank"><span>10.1002/14651858.CD008721</span></a>] <ul class="citation-link-group"> <li> <a class="citation-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/PNSXR55MMF3C635QN7UXZ3JPMNYXN/scholar_lookup?title=Anti%E2%80%90vascular+endothelial+growth+factor+for+proliferative+diabetic+retinopathy+(Protocol)&author=MJ+Martinez%E2%80%90Zapata&author=AJ+Mart%C3%AD%E2%80%90Carvajal&author=I+Sol%C3%A0&author=JI+Pijo%C3%A1n&author=JA+Buil%E2%80%90Calvo&publication_year=2010&hl=en" target="_blank"> <span>Google Scholar</span> </a> </li> </ul> </div> </div> </div> </section> </section> <section class="characteristicStudies" id="characteristicStudies"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title"> Characteristics of studies <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="characteristicIncludedStudiesContent" lang=""> <div class="section-header" id="CD008721-sec2-0024"> <h3 class="title">Characteristics of included studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008721-sec2-0025" class="jump-to">excluded studies</a></li> <li><a href="#CD008721-sec2-0026" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ahmadieh 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, double‐blind clinical trial of intravitreal bevacizumab for prevention of early post‐vitrectomy haemorrhage in people with diabetes </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: the eye, but 1 eye only of each person was included in the study</p> <p>Follow‐up: 1 week and 1 month after surgery</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Iran</p> <p>Setting: Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran </p> <p>Number of participants: 68 (68 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 34</p> <p>Age (mean (SD)): 53.69 (11.7) years in bevacizumab plus vitrectomy group, 56.70 (10.4) years in sham plus vitrectomy group </p> <p>Gender: 34 men and 34 women</p> <p>Inclusion criteria: indications for pars plana vitrectomia for complications of PDR existed such as non‐clearing VH, TRD involving or threatening the macula and active progressive PDR </p> <p>Exclusion criteria: BCVA of 20/40 or better, pregnancy, history of intravitreal bevacizumab injection, intraoperative use of long‐acting gas or silicone oil, and simultaneous intraocular surgery such as cataract extraction. Monocular participants </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal injection of bevacizumab 1.25 mg/0.05 mL 1 week before vitrectomy</p> <p>Control: sham injection and vitrectomy</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: incidence of early (4 weeks) postoperative VH at 1 week and 1 month after vitrectomy </p> <p>Secondary: mean change in BCVA and any bevacizumab‐related adverse event</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: NCT00524875</p> <p>Date conducted: not reported</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Randomization was performed by random block permutation according to a computer‐generated randomization list" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Details of the series were unknown to the investigators"</p> <p>Comment: there was not specified the allocation concealment</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Subjects were masked to the treatment method"</p> <p>Comment: surgeons were not blinded to the interventions assessed</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Visual acuity was measured by an optometrist who was masked to the groups. All preoperative and postoperative examinations were performed by one of the authors (NS), who also was masked to the study group identification" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were a 50% of losses during the study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ahn 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, clinical trial of intravitreal bevacizumab for preventing postvitrectomy haemorrhage in PDR </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: the eye, but 1 eye of each participant was included in the study. However, if the study eye completed 6 months of follow‐up, the contralateral eye requiring vitrectomy also was allowed to enrol in this study. A total of 107 eyes of 91 participants, of which there were 16 bilateral participants, were included for analysis </p> <p>Follow‐up: 1 day, 1 week, 1, 3 and 6 months after surgery</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Korea</p> <p>Setting: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea </p> <p>Number of participants: 91 (107 eyes)</p> <p>Exclusions post‐randomisation: 2</p> <p>Losses to follow‐up: 17</p> <p>Age (mean (SD)): 51.0 (9.5) years in preoperative bevacizumab group, 55.6 (SD 10.3) years in intraoperative bevacizumab group, 55.0 (11.4) years in control group </p> <p>Gender: 60 men and 47 women</p> <p>Inclusion criteria: people that needed pars plana vitrectomy due to PDR‐related complications such as non‐clearing VH, macula‐involving or macula‐threatening TRD or fibrovascular proliferation with vitreoretinal adhesions </p> <p>Exclusion criteria: follow‐up period of &lt; 6 months, intraoperative use of long‐acting gas or silicone oil, repeat vitrectomy after first vitrectomy for retinal diseases other than VH, previous history of vitrectomy, uncontrolled hypertension, medical history of blood coagulopathy, interval between bevacizumab injection and pars plana vitrectomy &gt; 2 weeks, or &lt; 3 months of bevacizumab treatment </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1 ‐ preoperative bevacizumab: intravitreal bevacizumab 1.25 mg/0.05 mL injection 1‐14 days before postoperative VH </p> <p>Treatment group 2 ‐ intraoperative bevacizumab: intravitreal bevacizumab 1.25 mg/0.05 mL injection at the end of postoperative VH </p> <p>Control: no injection and vitrectomy</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: incidence of early (4 weeks) and late (4 weeks) recurrent VH</p> <p>Secondary: initial time of vitreous clearing, BCVA at 6 months after surgery and adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: NTC00745498</p> <p>Date conducted: not reported</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Randomization was carried out using permuted block randomization with equal allocation ratio" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the lack of double‐masking, leaving room for possible bias"</p> <p>Comment: the authors say the study was not blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the lack of double‐masking, leaving room for possible bias"</p> <p>Comment: the authors say the study was not blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were 0 losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Cheema 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, clinical trial of intravitreal bevacizumab in cataract surgery for preventing progression of diabetic retinopathy </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: the eye, but 1 eye of each participant was included in the study</p> <p>Follow‐up: 1 day; 1, 2 and 4 weeks and then at monthly intervals for 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Saudi Arabia</p> <p>Setting: hospital, Dhahran, Kingdom of Saudi Arabia</p> <p>Number of participants: 68 (68 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean): 66.14 years in bevacizumab group, 64.5 years in control group</p> <p>Gender: 43 men and 25 women</p> <p>Inclusion criteria: cataract in people with diabetes with poor fundus view with 1. the presence of clinically significant macular oedema, 2. mild, moderate, severe or very severe non‐PDR or PDR or 3. a combination of 1 and 2; people with previous focal or grid laser photocoagulation for macular oedema </p> <p>Exclusion criteria: eyes with glaucoma, uveitis and age‐related macular degeneration or a history of trauma or ocular surgery; people with previous panretinal laser photocoagulation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: phacoemulsification with intraocular lens implantation and intravitreal bevacizumab 1.25 mg at the end of surgery </p> <p>Control: phacoemulsification with intraocular lens implantation alone</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: progression of postoperative diabetic retinopathy and diabetic maculopathy during a 6‐month follow‐up </p> <p>Secondary: change in BCVA, changes in central macular thickness and macular thickness determined by optical coherence tomography, postoperative laser therapy, progression to neovascular glaucoma </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: the participants were recruited between February and December 2007</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "The patients were randomized to a standardized procedure of phacoemulsification with IOL [intraocular lens] implantation alone (control group) or to receive 1.25 mg intravitreal bevacizumab (Avastin) at the end of surgery (intervention group)" </p> <p>Comment: not described how it was generated the random</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Progression of DR [diabetic retinopathy] was based on assessment in a masked fashion by 2 retina specialists (R.A.C., Y.M.A.)" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were 0 losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Cho 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, clinical trial of intravitreal bevacizumab and intravitreal triamcinolone as adjunctive treatments to PRP in diabetic retinopathy </p> <p>Unit of randomisation: eye</p> <p>Unit of analyses: eye</p> <p>Follow‐up: 1 day, 1 week, 1 and 3 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Korea</p> <p>Setting: Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea </p> <p>Number of participants: 76 (91 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (SD)): 50.96 (46.0) years in bevacizumab group, 51.06 (26.0) years in triamcinolone group </p> <p>Gender: 55 men and 21 women</p> <p>Inclusion criteria: aged ≥ 18 years, very severe non‐PDR to high‐risk PDR, Snellen BCVA of ≥ 3 </p> <p>Exclusion criteria: blood pressure &gt; 180 mmHg (systolic) and &gt; 110 mmHg (diastolic), glycated haemoglobin levels &gt; 9.5%, chronic renal failure, major surgery within 1 month, or previous systemic steroids or anti‐VEGF treatment. Ocular conditions other than diabetic retinopathy (e.g. retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.). History of treatment for diabetic macular oedema, PRP or focal/grid laser photocoagulation, or previous intraocular surgery, or uncontrolled glaucoma in the last 3 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1: intravitreal bevacizumab 1.25 mg/0.05 mL, 1 week before PRP</p> <p>Treatment group 2: intravitreal triamcinolone 4 mg/0.1 mL, 1 day after PRP</p> <p>Control: PRP</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: changes in BCVA and central macular thickness at 1 and 3 months</p> <p>Secondary: proportion of visual gain or loss, decreased or increased central macular thickness, adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: no financial interest of the authors</p> <p>Trial registration: not reported</p> <p>Date conducted: March 2007 to August 2008</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were no losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: incomplete results of the principal variable were described in the methods section </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Di Lauro 2010 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, clinical trial of intravitreal bevacizumab for surgical treatment of severe PDR </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: eye/participant</p> <p>Follow‐up: 1, 6, 12 and 24 weeks after the surgery</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Italy</p> <p>Setting: Department of Ophthalmology, Hospital C.T.O. of Naples, Naples, Italy</p> <p>Number of participants: 68 (72 eyes)</p> <p>Exclusions post‐randomisation: 3 (regression of the haemorrhage in a bevacizumab group)</p> <p>Losses to follow‐up: 0</p> <p>Age: not reported</p> <p>Gender: not reported</p> <p>Inclusion criteria: people affected by VH and TRD consequent to active PDR</p> <p>Exclusion criteria: people with neovascular glaucoma or cataract (or both) and cases of combined traction and rhegmatogenous retinal diabetes (diagnosed either before or during the surgery) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment group 1: intravitreal bevacizumab 1.25 mg/0.05 mL, 7 days before vitrectomy</p> <p>Treatment group 2: intravitreal bevacizumab 1.25 mg/0.05 mL, 20 days before vitrectomy</p> <p>Control: sham injection 20 days before vitrectomy</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: clearing of VH, incidence of adverse effects and the need of other procedures during the surgery </p> <p>Secondary: change in BCVA and duration of surgery</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: NCT01025934</p> <p>Date conducted: October 2005 to May 2007</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Patients in group A [control] were given a subconjunctival injection of 0.05 ml of BSS (Blood saline serum) 3 weeks before the vitrectomy" </p> <p>Comment: control received a sham intervention. The participant was blind to the treatment received. However, it is possible that the personnel that administered the sham were aware of treatment because the site of application was subconjunctival and not intravitreal as with bevacizumab </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "Patients in group A [control] were given a subconjunctival injection of 0.05 ml of BSS (Blood saline serum) 3 weeks before the vitrectomy" </p> <p>Comment: control received a sham intervention. The outcome assessor was blinded to the treatment administered </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were 3 losses post‐randomisation, but losses during follow‐up were not noted</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were reported in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">DRCR.Net 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: phase 3, double‐blind, randomised, multicentre clinical trial of intravitreal ranibizumab for VH from PDR </p> <p>Unit of randomisation: eye (1 eye per participant)</p> <p>Unit of analyses: eye</p> <p>Follow‐up: at 4, 8, 12 and 16 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA</p> <p>Setting: community‐based and academic‐based ophthalmology practices specialising in retinal diseases (61 centres) </p> <p>Number of participants: 261 (261 eyes)</p> <p>Exclusions post‐randomisation: 10 (3 in ranibizumab group and 7 in the control group)</p> <p>Losses to follow‐up: 4 (2 in each group)</p> <p>Age (mean (SD)): 58 (12) years</p> <p>Gender: 52% women</p> <p>Inclusion criteria: ≥ 18 years of age with type 1 or type 2 diabetes. Eyes with VH associated to PDR, causing vision impairment and precluding completion of PRP </p> <p>Exclusion criteria: eyes requiring immediate vitrectomy for reasons such as rhegmatogenous or traction retinal detachment; vision of no light perception, neovascular glaucoma, active iris neovascularisation judged or angle neovascularisation; history of intravitreal anti‐VEGF treatment for VH </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal ranibizumab 0.5 mg at baseline and 4 and 8 weeks</p> <p>Control: intravitreal saline at baseline and 4 and 8 weeks</p> <p>Both groups received PRP as soon as possible after the first injection</p> <p>Duration: 3 doses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: cumulative probability of vitrectomy performed within 16 weeks</p> <p>Secondary: the proportion of eyes with "complete" PRP by 16 weeks in the absence of vitrectomy; improvement in visual acuity from baseline to the 12‐week follow‐up visit; extent of VH measured by optical coherence tomography signal strength; systemic and ocular adverse events </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: co‐operative agreements EY14231 and EY18817 from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services (USA). Genentech provided the ranibizumab for the study and provided funds to DRCR.net </p> <p>Trial registration: NCT00996437</p> <p>Date conducted: June 2010 to March 2012</p> <p>Conflict of interest: Genentech provided the ranibizumab for the study and provided funds to DRCR.net to defray the study's clinical site costs. DRCR.net had complete control over the design of the protocol, conduct, and reporting of the research and retained ownership of the data </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: it was not specified how the random sequence was generated. Only specified that used a permuted block design stratified by site </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "randomly assigned on the DRCR.net website"</p> <p>Comment: the randomisation was centralised and the investigator were blinded to the random sequence </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "eyes received an injection of saline or 0.5‐mg ranibizumab at randomization, 4 weeks, and 8 weeks using a masked vial provided by the Coordinating Center that was identified by number only" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "eyes received an injection of saline or 0.5‐mg ranibizumab at randomization, 4 weeks, and 8 weeks using a masked vial provided by the Coordinating Center that was identified by number only" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the analyses were by intention to treat, and there were 4 losses of follow‐up (2 in each group) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the outcomes were specified in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">El‐Batarny 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised trial of intravitreal bevacizumab as an adjunctive treatment before diabetic vitrectomy </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: eye/participant</p> <p>Follow‐up: 1 day, 1 week, 2 weeks, 1 month after surgery and monthly up to the end of the follow‐up (mean 12 months; range 7‐18 months) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Sultanate of Oman</p> <p>Setting: Magrabi Eye and Ear Hospital, Muscat, Sultanate of Oman</p> <p>Number of participants: 30 (30 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (SD)): 44 (11) years in bevacizumab plus vitrectomy group, 46 (12) years in vitrectomy alone group </p> <p>Gender: not reported</p> <p>Inclusion criteria: people with indications for vitrectomia for complications of PDR existed such as TRD involving or treating the macula, not resolving VH, pre‐retinal subhyaloid bleeding </p> <p>Exclusion criteria: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal injection of bevacizumab 1.25 mg/0.05 mL, 5‐7 days before vitrectomy </p> <p>Control: vitrectomy alone</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: feasibility of the surgery and postoperative complications</p> <p>Secondary: visual acuity at 6 months of follow‐up, any bevacizumab‐related adverse event </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: not reported</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were 0 losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ergur 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised clinical trial of intravitreal bevacizumab for PDR </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: eye</p> <p>Follow‐up: 1 day, 1 week, 1 and 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Turkey</p> <p>Setting: M.D., Ministry of Health Atatürk Research and Training Hospital 2st Eye Clinic Ankara, Turkey </p> <p>Number of participants: 16 (19 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (SD)): 71.4 (4.6) years in bevacizumab plus PRP group, 68.3 (3.4) years in PRP group </p> <p>Gender: 9 men and 7 women</p> <p>Inclusion criteria: people with PDR</p> <p>Exclusion criteria: people with history of cataract surgery or thromboembolic ictus</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal bevacizumab 1.25 mg/0.05 mL, 20 days before PRP, 3 sessions</p> <p>Control: PRP/week/3 weeks, 3 sessions</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: BCVA, intraocular pressure, biomicroscopic examination, fundus examination, colour fundus photography, fluorescein leakage areas </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: not reported</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were 0 losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ernst 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, clinical trial of intravitreal bevacizumab for treatment of naive PDR and severe non‐PDR </p> <p>Unit of randomisation: eye</p> <p>Unit of analyses: eye</p> <p>Follow‐up: 1, 2, 6 and 12 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Mexico</p> <p>Setting: Asociación para Evitar la Ceguera en México</p> <p>Number of participants: 15 (20 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 5</p> <p>Age (mean (SD)): 53.3 (9) years</p> <p>Gender: 4 men and 6 women</p> <p>Inclusion criteria: people with type 2 diabetes mellitus and symmetric untreated severe naive PDR or PDR without macular oedema or prior intraocular surgery </p> <p>Exclusion criteria: people with history of myocardial infarction or cerebrovascular accident, retinal detachment, VH, previous treatment for diabetic retinopathy, media opacities that precluded visualisation of the fundus, pregnancy and inability to understands the implications of the protocol </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal bevacizumab 2.5 mg/0.1 mL every 2 months for 12 months (6 injections in total) </p> <p>Control: PRP, 2 sessions. A third session was administered if there was neovascularisation</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: BCVA, macular thickness, median deviation in visual fields at 1 year, and score on a participant satisfaction scale at 6 months and 1 year </p> <p>Secondary: complications associated to the treatments</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: NCT00347698</p> <p>Date conducted: March 2006 to August 2007</p> <p>Conflict of interest: none reported</p> <p>This study was designed using both treatments in the same participant: intravitreal bevacizumab in 1 eye compared with PRP in the contralateral eye </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the right eye was randomly assigned to treatment with PRP or intravitreal bevacizumab, and the left eye received the other treatment" </p> <p>Comment: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: open‐label study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The initial number of participants was 30, but only 15 participants were included and there was 5 losses </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Some results of variables specified in the published protocol were not reported: median deviation in visual fields at 1 year, and score on a participant satisfaction scale at 6 months and 1 year </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Farahvash 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: randomised, clinical trial in people with diabetes with indication for vitrectomy </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: participant/eye</p> <p>Follow‐up: first day, first week, first month, and then every 3 months until the last visit. Median: 8 months (range 3‐15 months) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Iran</p> <p>Setting: hospital</p> <p>Number of participants: 35 (35 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (range)): 58 (37‐73) years</p> <p>Gender: 18 men and 17 women</p> <p>Inclusion criteria: people with indications for vitrectomy. The indications were "persistent vitreous hemorrhage &gt;1 month in a patient with no history of PRP, nonclearing vitreous hemorrhage in a patient with history of complete PRP, vitreous hemorrhage with neovascularization of iris, vitreous hemorrhage with glaucoma, and vitreous hemorrhage with retinal detachment (based on the echography)" </p> <p>Exclusion criteria: "history of vitrectomy or any intraocular injection in the study eye or history of IVB [intravitreal bevacizumab injection] in either eye, previous myocardial infarction, cerebrovascular accident or thromboembolic event, uncontrolled hypertension, coagulation abnormalities, or current use of any anticoagulants but aspirin (aspirin was discontinued 1 week before injection) and those with unstable medical conditions" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal injection bevacizumab 1.25 mg 7 days prior to surgery</p> <p>Control: no treatment before surgery and vitrectomy</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: severity of intraoperative bleeding and break formation (based in surgeons observation) </p> <p>Secondary: visual acuity, complete attachment of the retina, complications</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: January 2008 to January 2009</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "in each subgroup, the patients were randomly assigned to injection of bevacizumab preoperatively (injection group) or not (control group) </p> <p>Comment: not described the method of randomization</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the surgeons were masked regarding patient groups and subgroup"</p> <p>Comment: not clear if the participants were blinded to the intervention</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the surgeons were masked regarding patient groups and subgroup"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were no losses for the main outcome</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section. SD of the BCVA after intervention were missing </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">González 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: randomised, prospective, open‐label direct comparison of pegaptanib alone with PRP alone in people with PDR </p> <p>Unit of randomisation: eyes (Quote: "for subjects in whom both eyes were eligible, one eye was selected randomly as the study eye. Fellow eyes of these subjects were treated according to standard clinical guidelines established") </p> <p>Unit of analyses: eye</p> <p>Follow‐up: 30 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA</p> <p>Setting: Valley Retina Institute</p> <p>Number of participants: 20 (20 eyes)</p> <p>Exclusions post‐randomisation: 1</p> <p>Losses to follow‐up: 3</p> <p>Age (mean): 56.2 years in intravitreal pentaganib group, 59 years in PRP group</p> <p>Gender: 13 men and 7 women</p> <p>Inclusion criteria: active PDR, in 1 or both eyes, with at least 1 of the following high‐risk characteristics as defined by the Diabetic Retinopathy Study: 1. new vessels within 1 disc diameter of the optic nerve head that were larger than one‐third of the disc area; 2. VH or pre‐retinal haemorrhage associated with either less extensive new vessels at the optic disc, or with new vessels elsewhere half the disc area or larger; or both 1. and 2. </p> <p>Exclusion criteria: haemorrhage or media opacity obscuring visualisation of the macula and optic nerve; epiretinal membranes involving the macula; proliferative diabetic membranes along the major retinal arcades sufficiently extensive to cause either significant vitreomacular traction or significant impairment in BCVA; any TRD; severe ischaemia involving the foveal avascular zone; neovascular glaucoma; study eye treated with intravitreal steroid injections within 6 months prior to baseline or PRP treatment within 90 days of baseline (or both) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal pentaganib 0.3 mg every 6 weeks for 30 weeks</p> <p>Control: PRP laser every 6 weeks for 30 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: regression of PDR from baseline to week 36, defined as regression of neovascularisation of the optic disc , neovascularisation elsewhere, or both </p> <p>Secondary: BCVA assessed by ETDRS letter score, as well as changes in optical coherence tomography assessments of central macular thickness and macular volume </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: grant from Pfizer, New York and (OSI) Eyetech, New York</p> <p>Trial registration: not reported</p> <p>Date conducted: not reported</p> <p>Conflict of interest: first author was a paid consultant and speaker for (OSI) Eyetech Pharmaceuticals </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "eligible eyes were randomly assigned (1:1) to either pegaptanib alone or PRP alone based on a sequence generated by the random number function in Microsoft Excel (Microsoft Corporation, Seattle, Washington)" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "prospective, randomised, controlled, open‐label, exploratory study"</p> <p>Comment: the participants and personnel were not blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "prospective, randomised, controlled, open‐label, exploratory study"</p> <p>Comment: the outcome assessor was not blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were 4 losses (2 in each group)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Mirshahi 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, double‐blind clinical trial of intravitreal bevacizumab in PDR </p> <p>Unit of randomisation: eye</p> <p>Unit of analyses: eye</p> <p>Follow‐up: 6 and 16 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Iran</p> <p>Setting: Eye Research Center, Farabi Eye Hospital, Medical Sciences/University of Tehran </p> <p>Number of participants: 40 (80 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (median (range)): 52 (39‐68) years</p> <p>Gender: 12 men and 28 women</p> <p>Inclusion criteria: people with high‐risk characteristics identified by Diabetic Retinopathy Study criteria: neovascularisation of the disc ≥ one‐quarter to one/third disc area, any amount of disc neovascularisation with VH or pre‐retinal haemorrhage, or neovascularisation elsewhere ≥ one‐half disc area with VH or pre‐retinal haemorrhage (with or without macular oedema) </p> <p>Exclusion criteria: people with uncontrolled hypertension, recent (in the past 6 months) myocardial infarction or cerebrovascular accident, uncontrolled glaucoma, a history of any type of retinal photocoagulation, a diagnosis of TRD </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal injection bevacizumab 1.25 mg/0.05 mL at the first session of laser photocoagulation and 3 sessions of laser photocoagulation (1 week apart) </p> <p>Control: sham injection in the fellow eye at the first session of laser photocoagulation and 3 sessions of laser photocoagulation (1 week apart) </p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: regression response was defined angiographically</p> <p>Secondary: recurrence of PDR and complications of treatment</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: December 2005 to September 2006</p> <p>Conflict of interest: none reported</p> <p>This study was designed using both treatments in the same participant: intravitreal bevacizumab in 1 eye compared with PRP in the contralateral eye </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "fellow eyes of each case were randomly assigned to receive Avastin [bevacizumab] or sham" </p> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "fellow eye injection was mimicked with a needleless syringe"</p> <p>Comment: personnel were not blinded, but the participants were blinded</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "this assessment was carried out by two independent masked observers; in case of conflict it was resolved through discussion" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There were 0 losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Modarres 2009 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective surgeon‐blinded randomised clinical trial in people undergoing pars plana vitrectomy for complications of PDR </p> <p>Unit of randomisation: eye</p> <p>Unit of analyses: eye</p> <p>Follow‐up: mean (SD) 7 (3.6) months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Iran</p> <p>Setting: Department of Ophthalmology</p> <p>Number of participants: 40 (40 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (SD)): 55.8 (11.3) years in bevacizumab group, 53.2 (SD 11.7) years in control group </p> <p>Gender: not reported</p> <p>Inclusion criteria: people with diabetes who were candidates for vitrectomy with complexity scores of 4‐8 </p> <p>Exclusion criteria: presence of significant cataract that caused impairment of vision, previous vitreoretinal surgery, previous intravitreal bevacizumab injection and the presence of any other vitreoretinal pathology </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal bevacizumab 2.5 mg 3‐5 days before operation</p> <p>Control: no preoperative injection was performed</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: facilitation of the surgery (number of endodiathermy applications, backflush needle applications, duration of surgery, type of tamponade) and decrease of complications (postoperative VH) </p> <p>Secondary: anatomic and visual outcomes (3‐month postoperative BCVA as well as visual acuity at the last follow‐up) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: not reported</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "prospective surgeon‐masked randomized clinical trial. The surgeons (MM, MH, MN, and MMP) were masked as to injection. During each operation, the number of endodiathermy applications, backflush needle applications, and the duration of surgery were recorded by an independent observer" </p> <p>Comment: the blinding of the participants was not mentioned. The participants were either given an injection or not of bevacizumab. Therefore, they would know which group they were in </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "prospective surgeon‐masked randomized clinical trial. The surgeons (MM, MH, MN, and MMP) were masked as to injection. During each operation, the number of endodiathermy applications, backflush needle applications, and the duration of surgery were recorded by an independent observer" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Losses during follow‐up were not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Preti 2014 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: prospective, randomised, blinded, controlled trial comparing of PRP with intravitreal bevacizumab injections versus PRP alone in high‐risk PDR </p> <p>Unit of randomisation: eye, within‐person study</p> <p>Unit of analyses: eye but not pair‐matched analysis</p> <p>Follow‐up: 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Brazil</p> <p>Setting: Department of Ophthalmology, University of Sap Paulo Medical School</p> <p>Number of participants: 42 (84 eyes)</p> <p>Exclusions post‐randomisation: 7 people with VH</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (range)): 56 (43‐73) years</p> <p>Gender: 28 men and 14 women</p> <p>Inclusion criteria: aged ≥ 18 years, high‐risk PDR with or without diabetic macular oedema; visual acuity ≥ 20/200 </p> <p>Exclusion criteria: pretreatment for diabetic retinopathy (laser, intraocular medications and surgeries); pre‐retinal haemorrhage and VH; presence of changes in the vitreous‐retinal interface (epiretinal membrane, macular hole and vitreoretinal traction syndrome); evidence of active external eye infection such as blepharitis; prior thromboembolic events, including myocardial infarction, stroke and deep vein thrombosis; systolic blood pressure &gt; 180 mm Hg and diastolic blood pressure &gt; 110 mm Hg; glycated haemoglobin levels &gt; 15%; chronic renal failure; major surgery within 1 month; previous systemic anti‐VEGF </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: 2 intravitreal bevacizumab injections 1.25 mg/0.05 mL, 1 dose 1 week before the PRP, and the other dose after the last session of PRP. The PRP was performed weekly over 3 weeks </p> <p>Control: PRP performed weekly over 3 weeks</p> <p>Duration: 4 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: changes in contrast sensitivity measured with Vistech Consultants Incorporation® (VCTS) at 1, 3 and 6 months between the groups with and without diabetic macular oedema </p> <p>Secondary: changes in VCTS within each group with and without diabetic macular oedema; ocular safety (ocular hypertension, lens opacity progression and anterior chamber reaction arterial); systemic safety (thromboembolic events) </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: study was supported by the Sao Paulo Research Foundation (FAPESP) No 2009/08895‐1</p> <p>Trial registration: NCT01389505</p> <p>Date conducted: February 2011 to June 2012</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: blinding not mentioned</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: blinding not mentioned</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7 post‐randomisation losses, not specified by group</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comments: outcome measures on clinical trials.gov were different to those reported in the paper: </p> <p>Primary outcome measures: functional macular evaluation [timeframe: 24 weeks] [designated as safety issue: yes]; during this 24 weeks of follow‐up the visual acuity (ETDRS), contrast vision will be measured at baseline, 4, 12 and finally at 24 weeks. </p> <p>Secondary outcome measures: structural macular evaluation [timeframe: 24 weeks] [designated as safety issue: yes]; during the 24 weeks of follow‐up the following measured will be made: optical coherence tomography </p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Ramos Filho 2011 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: randomised, clinical trial that assessed efficacy of ranibizumab in people with high‐risk PDR </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: participant/eye</p> <p>Follow‐up: 16, 32 and 48 weeks</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Brazil</p> <p>Setting: Department of Ophthalmology, School of Medicine</p> <p>Number of participants: 40 (40 eyes)</p> <p>Exclusions post‐randomisation: 1</p> <p>Losses to follow‐up: 10</p> <p>Age (mean): 50.5 years in ranibizumab plus PRP group, 63.3 years in PRP alone group</p> <p>Gender: 18 men and 11 women</p> <p>Inclusion criteria: people with high‐risk PDR, which was defined according to the guidelines set forth by the ETDRS: 1. presence of neovascularisation at the disc &gt; ETDRS standard photograph 10A, 2. presence of neovascularisation at the disc associated with VH or pre‐retinal haemorrhage or 3. neovascularisation elsewhere with more than one‐half disk area associated with VH or pre‐retinal haemorrhage </p> <p>Exclusion criteria: 1. history of prior laser treatment or vitrectomy in the study eye; 2. history of thromboembolic event, 3. major surgery within the prior 6 months or planned within the next 28 days; 4. uncontrolled hypertension, 5. known coagulation abnormalities or current use of anticoagulative medication other than aspirin or 6. any condition affecting documentation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal ranibizumab 0.5 mg, 60 minutes after the completion of PRP</p> <p>Control: PRP</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: total area (mm<sup>2</sup>) of fluorescein leakage from active neovascularisation </p> <p>Secondary: BCVA (logMAR) and the central subfield macular thickness</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). Grant number: 2009 ⁄ 01036‐3 </p> <p>Trial registration: NCT01988246</p> <p>Trial registration: not reported</p> <p>Date conducted: February 2009 to December 2009</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "The technician was asked to pick up one of two identical opaque envelopes; one contained the designation for PRP, and the other contained the designation for PRP plus treatment" </p> <p>Comment: the method of randomisation was not described. There was an imbalance between groups in the age of the participants (mean (SD): 63.3 (2.5) with intravitreal ranibizumab + PRP vs. 50.5 (3.0) with PRP alone; P value = 0.0036)), which suggest doubts about if they were correctly randomised </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the technician was asked to pick up one of two identical opaque envelopes; one contained the designation for PRP, and the other contained the designation for PRP plus treatment" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: blinding of participants and personnel were not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "a single masked certified examiner performed Early Treatment Diabetic Retinopathy Study (ETDRS) best‐corrected visual acuity (BCVA) measurements prior to any other study procedure. A single retinal specialist performed the ophthalmic evaluations (JARF) and the stereoscopic fundus photography (FPPA). Study data were analysed and interpreted by AM, RAC, IUS, JASR, RJ" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "twenty‐nine of 40 patients initially included in this trial completed the 48‐week follow‐up evaluation" </p> <p>Comment: there were 11 losses (27.5%)</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Rizzo 2008 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: randomised clinical trial in people undergoing pars plana vitrectomy for retinal detachment </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: participant/eye</p> <p>Follow‐up: 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Italy</p> <p>Setting: Eye Surgery Clinic</p> <p>Number of participants: 22 (22 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (range)): 52 (24‐63) years</p> <p>Gender: not described</p> <p>Inclusion criteria: TRD, tractional‐rhegmatogenous retinal detachment or tractional detachment complicated with VH </p> <p>Exclusion criteria: history of vitrectomy in the study eye, thromboembolic events, major surgery within the previous 3 months or planned within the next 28 days, uncontrolled hypertension, known coagulation abnormalities or current use of anticoagulative medication other than aspirin </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal bevacizumab 1.25 mg/0.05 mL, 5‐7 days before surgery</p> <p>Control: no preoperative injection</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: feasibility of the surgery</p> <p>Secondary: visual and anatomic outcome at 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: not reported</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "we used a table of random numbers in order to assign each study participant to group 1 or 2" </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there were 0 losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: there was no complete data for BCVA (SD)</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Sohn 2012 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: randomised double‐blind clinical trial</p> <p>Unit of randomisation: eye</p> <p>Unit of analyses: eye</p> <p>Follow‐up: 3 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: USA</p> <p>Setting: Department of Ophthalmology</p> <p>Number of participants: 19 (20 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 2</p> <p>Age (mean (range)): 52 (31‐64) years</p> <p>Gender: 12 men and 7 women</p> <p>Inclusion criteria: people with TRD or combined TRD/rhegmatogenous retinal detachment secondary to PDR who were given anaesthesia clearance for pars plana vitrectomy. Indications for pars plana vitrectomy included TRD involving the macula, TRD/rhegmatogenous retinal detachment and non‐clearing or recurrent VH precluding complete PRP with TRD not necessarily involving the macula </p> <p>Exclusion criteria: history of pars plana vitrectomy; dense VH preventing preoperative grading of fibrovascular membranes; an inability to return for pars plana vitrectomy within 3‐7 days after randomisation; a history of cerebrovascular accident, thromboembolic event or myocardial infarction within 6 months; aged &lt; 18 years and pregnancy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal bevacizumab injection 1.25 mg/0.05 mL, 3‐6 days before surgery</p> <p>Control: sham injection (1 syringe without a needle placed to simulate intravitreal injection) </p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: visual acuity at 3 months of follow‐up, vitreous levels of VEGF</p> <p>Secondary: amount of intraoperative bleeding</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: supported by: the Eugene de Juan Jr Award for Innovation (Dr Sohn); the Heed Foundation (Drs Kim and Javaheri); grant K12‐EY16335 from the National Eye Institute, National Institutes of Health (Dr Kim); The Arnold and Mabel Beckman Foundation (Dr Hinton); Research to Prevent Blindness (Department of Ophthalmology, University of Iowa Hospitals and Clinics); and core grant EY03040 from the National Eye Institute (Doheny Eye Institute) </p> <p>Trial registration: not reported</p> <p>Date conducted: not reported</p> <p>Conflict of interest: Dr Hinton served as a consultant to FibroGen, Inc. Dr Eliott served as an ad hoc consultant to Genentech </p> <p>Other comments: participants of the control group had more severe symptoms than the bevacizumab group at baseline: 2 had visually significant cataract (1 participant in each group), 2 had worsening ischaemia (in control group), 1 had severe neovascular glaucoma (in control group) and 1 had VH (in control group) </p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the patient and surgeon were masked to the patients' randomization group"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "the patient and surgeon were masked to the patients' randomization group"</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: only 2 participants (1 in each group) were lost during the follow‐up</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: the results of the variables were described in the methods section</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">Zaman 2013 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Study design: randomised, controlled trial comparing intravitreal bevacizumab injection 5‐7 days prior to pars plana vitrectomy versus pars plana vitrectomy alone </p> <p>Unit of randomisation: participant</p> <p>Unit of analyses: participant</p> <p>Follow‐up: 6 months</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Country: Pakistan</p> <p>Setting: Al‐Ibrahim Eye Hospital</p> <p>Number of participants: 54 (54 eyes)</p> <p>Exclusions post‐randomisation: 0</p> <p>Losses to follow‐up: 0</p> <p>Age (mean (range)): 52 (39‐67) years</p> <p>Gender: 32 men and 22 women</p> <p>Inclusion criteria: non‐clearing VH of at least 1 month; TRD involving or threatening the macula; pre‐retinal subhyaloid bleeding covering the macula </p> <p>Exclusion criteria: not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Treatment: intravitreal bevacizumab 1.25 mg/0.05 mL (Avastin, Genentech), 5‐7 days before PPV. Topical antibiotic (moxifloxacin) was started 1 day before the procedure and was continued for 3 days post injection </p> <p>Control: PPV alone</p> <p>Duration: only 1 dose</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Primary: improvement of BCVA after surgery, postoperative complications, hyphema, rubeosis, frequency of VH. Early postoperative VH was taken as VH occurring within 4 weeks after surgery. Later postoperative VH was taken as VH occurring within 5 weeks and 6 months </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="2" rowspan="1" bgcolor="#ffffff"> <p>Funding: not reported</p> <p>Trial registration: not reported</p> <p>Date conducted: September 2010 to August 2011</p> <p>Conflict of interest: none reported</p> </td> </tr> <tr> <td align="" valign="" colspan="3" rowspan="1" bgcolor="#ffffff"> <p><b><i>Risk of bias</i> </b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Bias</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Authors' judgement</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Random sequence generation (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Allocation concealment (selection bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: not described</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of participants and personnel (performance bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: blinding not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Blinding of outcome assessment (detection bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Unclear risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: blinding not reported</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Incomplete outcome data (attrition bias) <br> All outcomes </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "all cases completed a minimum follow up of 6 months"</p> <p>Comment: there were no losses</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Selective reporting (reporting bias)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Low risk</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Comment: in the paper the results of outcomes were specified in the methods section, but we have not access to the protocol to check if all outcomes were reported </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCVA: best‐corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation; SD: standard deviation; TRD: tractional retinal detachment; VEGF: vascular endothelial growth factor; VH: vitreous haemorrhage. </p> </div> </div> </p> </section> <section class="characteristicsOfExcludedStudies" lang=""> <div class="section-header" id="CD008721-sec2-0025"> <h3 class="title">Characteristics of excluded studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008721-sec2-0024" class="jump-to">included studies</a></li> <li><a href="#CD008721-sec2-0026" class="jump-to">ongoing studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Reason for exclusion</p> </td> </tr> </thead> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0019">Arimura 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Retrospective, comparative study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0020">Fulda 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial. Each participant received the 2 evaluated interventions. The right eye received intravitreal bevacizumab and 1 session of 800 scattered laser spots. The left eye underwent a full 1600 laser panretinal photocoagulation </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0021">Genovesi‐Ebert 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0022">Gonzalez 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RCT assessed the efficacy and safety of pegaptanib in treating diabetic macular oedema and diabetic retinopathy. The publication was an abstract and there was insufficient information to include the study. The principal focus is of participants with macular oedema </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0023">Hattori 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0024">Huang 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Compared with historical controls. Not randomised</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0025">Ip 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2 years of follow‐up to evaluate effects of intravitreal ranibizumab on diabetic retinopathy severity over time in 2 phase 3 clinical trials (RIDE, NCT00473382; RISE, NCT00473330) for diabetic macular oedema </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0026">Jiang 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Retrospective study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0027">Jorge 2006</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Non‐randomised study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0028">Lanzagorta‐Aresti 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>The included participants did not have proliferative diabetic retinopathy. The outcomes measured were central macular thickness and visual acuity in participants with a moderate retinopathy not proliferative that needed a cataract surgery </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0029">López‐López 2012</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Anti‐VEGF group was not randomised</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0030">Michaelides 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Focus of the clinical trial was diabetic macular oedema</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0031">Minnella 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Non‐controlled clinical trial</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0032">Scott 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Study evaluated agreement in diabetic retinopathy severity classification by retina specialists performing ophthalmoscopy vs. reading centre grading of 7‐field<br> stereoscopic fundus photographs in a phase 2 clinical trial of intravitreal bevacizumab for centre‐involved diabetic macular oedema </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0033">Shin 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Data were collected retrospectively</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0034">Stergiou 2007</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Retrospective case series</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0035">Tonello 2008</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Quote: "for patients (n= 8) presenting with high‐risk PDR [proliferative diabetic retinopathy] in both eyes, the eye with worse BCVA [best‐corrected visual acuity] was selected to receive PRP [panretinal photocoagulation] plus intravitreal bevacizumab (eight eyes) and the fellow eye was treated with PRP alone (eight eyes)" </p> <p>Comment: clinical trial partially randomised</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0036">Yeh 2009</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Not a randomised study. The treatment assignment was alternative</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><a href="references#CD008721-bbs2-0037">Zhou 2010</a> </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Focus of the clinical trial is diabetic macular oedema</p> </td> </tr> </tbody> </table> </div> </p> </section> <section class="characteristicsOfOngoingStudies" lang=""> <div class="section-header" id="CD008721-sec2-0026"> <h3 class="title">Characteristics of ongoing studies [ordered by study ID]</h3> <div class="jump-to"> <p>Jump to: </p> <ul class="jump-to-links"> <li><a href="#CD008721-sec2-0024" class="jump-to">included studies</a></li> <li><a href="#CD008721-sec2-0025" class="jump-to">excluded studies</a></li> </ul> </div> </div> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">EUCTR2013‐003272‐12‐GB </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>EUCTR2013‐003272‐12‐GB</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prospective, randomised, controlled, single‐masked study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>220 participants with proliferative diabetic retinopathy</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Aflibercept versus PRP laser treatment</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary:</p> <p> <ol id="CD008721-lst1-0008"> <li> <p>Difference in mean change in BCVA measured in ETDRS letter scores</p> </li> </ol> </p> <p>Secondary:</p> <p> <ol id="CD008721-lst1-0009"> <li> <p>To measure the effect of intravitreal aflibercept therapy, relative to PRP on additional visual functions and quality of life outcomes including: </p> <ol id="CD008721-lst2-0001"> <li> <p>unilateral and binocular Estermann visual fields defects</p> </li> <li> <p>binocular visual acuity and low luminance visual acuity</p> </li> <li> <p>visual acuity outcomes in terms of visual gain or loss</p> </li> <li> <p>contrast sensitivity using Pelli Robson charts</p> </li> <li> <p>vision‐related quality of life measured by VFQ‐25 (Visual Functioning Questionnaire 25) and RetDQoL ( Retinopathy‐Dependent Quality of Life) </p> </li> <li> <p>diabetic retinopathy treatment satisfaction outcomes (RetTSQ; Retinopathy Treatment Satisfaction Questionnaire) </p> </li> <li> <p>generic health‐related quality of life using the EQ‐5D, ICECAP‐A (ICEpop CAPability measure for Adults) and CSRI (Client Services Receipt Inventory) </p> </li> </ol> </li> <li> <p>To estimate incremental cost‐effectiveness of intravitreal aflibercept versus standard PRP treatment at 52 weeks </p> </li> <li> <p>To determine the proportions of treatment naive and post‐treatment PRP eyes in both groups that do not require PRP through 52 weeks after basic treatment of 3 loading doses of aflibercept or initial completion of PRP </p> </li> <li> <p>To compare between groups the regression pattern at 12 weeks and the regression and re‐activation patterns of retinal neovascularisation at 52 weeks </p> </li> <li> <p>To compare the proportion of participants with 1‐step and 3‐step improvement or worsening of diabetic retinopathy between treatment groups at 12 and 52 weeks as per schedule of assessment </p> </li> <li> <p>To explore the difference in safety profile between intravitreal aflibercept and PRP at 52 weeks, in terms of proportion of participants developing macular oedema (defined as central subfield thickness of &gt; 300 µm on spectral domain optical coherence tomography due to clinical evidence of macular oedema), any de novo or increase in existing vitreous haemorrhage, de novo or increasing tractional retinal detachment, neovascular glaucoma and requirement for vitrectomy. The indication for vitrectomy will be reported </p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>8 April 2014</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Natasha Ajraam. Moorfields Eye Hospital, London, UK</p> <p>e‐mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1d737c697c6e757c337c776f7c7c705d7072726f7b747871796e3373756e336876">[email&#160;protected]</a></p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Funding: Bayer PLC and NIHR MRC ‐ EME grant</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01854593 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NCT01854593</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prospective, randomised, controlled, double‐masked (participant and carer) study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>People with proliferative diabetic retinopathy and indication for primary vitrectomy</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intravitreal bevacizumab 0.16 mg versus sham injection</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>VEGF concentration in vitreous after intravitreal bevacizumab injection at 1 year</p> <p>Early (within 4 weeks) postoperative vitreous haemorrhage. Re‐operation due to vitreous haemorrhage </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>May 2012</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Ayumu Manabe. Nihon University, Japan</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01941329 (PROTEUS) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PROTEUS study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prospective, randomised, multicentre, open‐label, phase II‐III study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>People with high‐risk proliferative diabetic retinopathy. Number: 94</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intravitreal injection ranibizumab 0.5 mg plus PRP (group 1) vs. PRP alone (group 2) </p> <p>Group 1: 3 x intravitreal injections of ranibizumab combined with standard PRP (mean 2 (standard deviation 1) weeks after injection), at month 0, month 1 and month 2 that can be repeated after month 3, with always at least a 1‐month interval between injections </p> <p>Group 2: PRP between month 0 and month 2, with 1 mandatory laser session in month 0 and more laser sessions as needed until month 2 to complete the PRP treatment </p> <p>After completing the PRP treatment, PRP sessions can be repeated from month 3 to month 11 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary:</p> <p> <ol id="CD008721-lst1-0010"> <li> <p>Regression of neovascularisation at 12‐month treatment</p> </li> </ol> </p> <p>Secondary:</p> <p> <ol id="CD008721-lst1-0011"> <li> <p>Changes in BCVA at 12‐month treatment</p> </li> <li> <p>Time to complete neovascularisation regression at 12‐month treatment</p> </li> <li> <p>Recurrence of neovascularisation at 12‐month treatment</p> </li> <li> <p>Macular retinal thickness at 12‐month treatment</p> </li> <li> <p>Need of treatment for diabetic macular oedema at 12‐month treatment</p> </li> <li> <p>Need of vitrectomy due to the occurrence of vitreous haemorrhage, tractional retinal detachment or other complications of diabetic retinopathy at 12‐month treatment </p> </li> <li> <p>Adverse events related to the treatments at 12‐month treatment</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>April 2014</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>José Cunha‐Vaz, MD, PhD; mail: <a href="http://mailto:4c%40aibili.pt?subject=NCT01941329,%20ECR-RET-2013-05,%20Prospective,%20Randomized,%20Multicentre,%20Open-label,%20Phase%20II%20/%20III%20Study%20to%20Assess%20Efficacy%20and%20Safety%20of%20Ranibizumab%200.5%20mg%20Intravitreal%20Injections%20Plus%20Panretinal%20Photocoagulation%20(PRP)%20Versus%20PRP%20in%20Monotherapy%20in%20the%20Treatment%20of%20Subjects%20With%20High%20Risk%20Proliferative%20Diabetic%20Retinopathy." target="_blank"><span class="__cf_email__" data-cfemail="face99ba9b9398939693d48a8e">[email&#160;protected]</span></a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NCT01941329</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01976923 (PACORES) </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PACORES study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prospective, randomised, active‐controlled study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants with tractional retinal detachment secondary to proliferative diabetic retinopathy and indication for vitrectomy. Number: 374 </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Intravitreal bevacizumab 1.25 mg/0.05 mL versus small‐gauge pars plana vitrectomy</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary:</p> <p> <ol id="CD008721-lst1-0012"> <li> <p>Intraoperative bleeding at 12 months</p> </li> <li> <p>Total surgical time at 12 months</p> </li> <li> <p>Postoperative vitreous haemorrhage at 12 months</p> </li> <li> <p>Visual acuity change at 12 months</p> </li> </ol> </p> <p>Secondary:</p> <p> <ol id="CD008721-lst1-0013"> <li> <p>Number of endodiathermy applications at 12 months</p> </li> <li> <p>Intraoperative breaks at 12 months</p> </li> <li> <p>Change in central macular thickness at 12 months</p> </li> <li> <p>Proportion of eyes gaining at least 15 letters of BCVA at 12 months</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>November 2013</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>J. Fernando Arevalo, MD, FACS; mail: <a href="http://mailto:arevalojf%40jhmi.edu" target="_blank"><span class="__cf_email__" data-cfemail="b3d2c1d6c5d2dfdcd9d5f3d9dbdeda9dd6d7c6">[email&#160;protected]</span></a> </p> <p>Igor Kozak, MD; mail: <a href="http://mailto:ikozak%40kkesh.med.sa" target="_blank"><span class="__cf_email__" data-cfemail="492022263328220922222c3a2167242c2d673a28">[email&#160;protected]</span></a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>NCT01976923</p> </td> </tr> </tbody> </table> </div> <div class="table" id=""> <table> <div class="table-heading"><span class="table-label"></span><span class="table-title">NCT01988246 </span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Trial name or title</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>PROMISE</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Methods</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prospective, randomised, controlled, single‐masked (participant) study</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Participants</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Prevention of macular oedema in participants with diabetic retinopathy undergoing cataract surgery </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Interventions</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Aflibercept 2 mg intravitreal injection (0.05 mL or 50 μL) administered at time of surgery (post cataract excision) versus sham injection </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcomes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Primary:</p> <p> <ol id="CD008721-lst1-0014"> <li> <p>Safety and efficacy at day 90</p> </li> <li> <p>Incidence and severity of ocular and non‐ocular adverse events and serious adverse events between treatment arms </p> </li> </ol> </p> <p>Secondary:</p> <p> <ol id="CD008721-lst1-0015"> <li> <p>Visual acuity at day 90</p> </li> <li> <p>Change from baseline in BCVA score at day 90 as measured by ETDRS</p> </li> <li> <p>Macular oedema at day 90</p> </li> <li> <p>Macular oedema as measured by spectral domain ocular coherence tomography at day 90</p> </li> </ol> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Starting date</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>December 2013</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Contact information</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Rishi Singh, M.D.; mail: <a href="http://mailto:singhr%40ccf.org?subject=NCT01988246,%20PROMISE%20Trial,%20Prevention%20of%20Macular%20Edema%20In%20Patients%20With%20Diabetic%20Retinopathy%20Undergoing%20Cataract%20Surgery" target="_blank"><span class="__cf_email__" data-cfemail="a5d6cccbc2cdd7e5c6c6c38bcad7c2">[email&#160;protected]</span></a> </p> <p>Gail Kolin, BSN RN; mail: <a href="http://mailto:koling%40ccf.org?subject=NCT01988246,%20PROMISE%20Trial,%20Prevention%20of%20Macular%20Edema%20In%20Patients%20With%20Diabetic%20Retinopathy%20Undergoing%20Cataract%20Surgery" target="_blank"><span class="__cf_email__" data-cfemail="0863676461666f486b6b6e26677a6f">[email&#160;protected]</span></a> </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Notes</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>There will be participants with non‐proliferative diabetic retinopathy</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BCVA: best‐corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; PRP: panretinal photocoagulation; VEGF: vascular endothelial growth factor. </p> </div> </div> </p> </section> </section> <section class="dataAndAnalyses" id="dataAndAnalyses"> <section class="dataAndAnalyses" lang="en"> <div class="section-header section-collapse-header" id="CD008721-sec1-0011"> <h2 class="title section-collapse-title">Data and analyses<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <div class="table" id="CD008721-tbl-0003"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>373</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.07 [‐0.12, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00101"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-01.png?filename=nCD008721-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%201%20Visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.1</div> </div> <hr class="top"><img data-id="CD008721-fig-00101" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-01.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 1 Visual acuity."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 1 Visual acuity. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Pegaptanib</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.06 [‐0.22, 0.10]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Bevacizumab</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 [‐0.11, 0.09]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Ranibizumab</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>277</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.10 [‐0.16, ‐0.03]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Regression of proliferative diabetic retinopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00102"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-02.png?filename=nCD008721-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%202%20Regression%20of%20proliferative%20diabetic%20retinopathy.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.2</div> </div> <hr class="top"><img data-id="CD008721-fig-00102" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-02.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 2 Regression of proliferative diabetic retinopathy."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 2 Regression of proliferative diabetic retinopathy. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Presence of vitreous or pre‐retinal haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>342</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.32 [0.16, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00103"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-03.png?filename=nCD008721-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%203%20Presence%20of%20vitreous%20or%20pre%E2%80%90retinal%20haemorrhage.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.3</div> </div> <hr class="top"><img data-id="CD008721-fig-00103" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-03.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 3 Presence of vitreous or pre‐retinal haemorrhage."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 3 Presence of vitreous or pre‐retinal haemorrhage. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Bevacizumab</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.11 [0.01, 1.92]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Pegaptanib</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.2 [0.01, 3.70]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 Ranibizumab versus control</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.38 [0.18, 0.81]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00104"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-04.png?filename=nCD008721-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%204%20Adverse%20effects.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 1.4</div> </div> <hr class="top"><img data-id="CD008721-fig-00104" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-04.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 4 Adverse effects."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 4 Adverse effects. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 Neovascular glaucoma</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 [0.07, 17.21]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 Retinal detachment</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.99 [0.44, 2.25]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.3 Cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.32 [0.01, 7.63]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.4 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>322</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.75 [0.42, 1.36]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.5 Cerebrovascular accident</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>322</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.26 [0.13, 79.34]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.6 Endophalmitis</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.36 [0.01, 8.82]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7 Arterial hypertension</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.47 [0.12, 1.76]</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD008721-tbl-0004"> <table class="comparison"><a href="#0" class="open-table-viewer open-in-figure-viewer">Open in table viewer</a><div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Bevacizumab with vitrectomy compared with vitrectomy alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Loss of 3 or more lines of ETDRS visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.49 [0.08, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00201"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-01.png?filename=nCD008721-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%201%20Loss%20of%203%20or%20more%20lines%20of%20ETDRS%20visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.1</div> </div> <hr class="top"><img data-id="CD008721-fig-00201" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-01.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 1 Loss of 3 or more lines of ETDRS visual acuity."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 1 Loss of 3 or more lines of ETDRS visual acuity. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Gain of 3 or more lines of ETDRS visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.62 [1.20, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00202"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-02.png?filename=nCD008721-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%202%20Gain%20of%203%20or%20more%20lines%20of%20ETDRS%20visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.2</div> </div> <hr class="top"><img data-id="CD008721-fig-00202" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-02.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 2 Gain of 3 or more lines of ETDRS visual acuity."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 2 Gain of 3 or more lines of ETDRS visual acuity. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>335</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.24 [‐0.50, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00203"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-03.png?filename=nCD008721-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%203%20Visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.3</div> </div> <hr class="top"><img data-id="CD008721-fig-00203" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-03.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 3 Visual acuity."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 3 Visual acuity. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Presence of vitreous or pre‐retinal haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>393</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.30 [0.18, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00204"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-04.png?filename=nCD008721-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%204%20Presence%20of%20vitreous%20or%20pre%E2%80%90retinal%20haemorrhage.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.4</div> </div> <hr class="top"><img data-id="CD008721-fig-00204" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-04.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 4 Presence of vitreous or pre‐retinal haemorrhage."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 4 Presence of vitreous or pre‐retinal haemorrhage. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"> <div class="figure" id="CD008721-fig-00205"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <li><a href="#0" class="open-in-figure-viewer">Open in figure viewer</a></li> <li><a class="btn btn-link" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-05.png?filename=nCD008721-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%205%20Adverse%20effects.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a></li> </nav> <div class="figure-label">Analysis 2.5</div> </div> <hr class="top"><img data-id="CD008721-fig-00205" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-05.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 5 Adverse effects."><hr class="bottom"> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 5 Adverse effects. </p> </div> </div> </div> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Neovascular glaucoma</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>107</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.33 [0.28, 19.17]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Retinal detachment</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>182</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.56 [0.11, 2.86]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.3 Cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>137</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.68 [0.38, 1.23]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.4 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>68</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.31 [0.01, 7.47]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.5 Myocardial infarction</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>175</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.6 Cerebrovascular accident</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>175</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.7 Arterial hypertension</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> </div> </section> </section> <div class="figures-list"> <div class="figure" id="CD008721-fig-0001"> <img data-id="CD008721-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG01.png" alt="Results from searching for studies for inclusion in the review."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Results from searching for studies for inclusion in the review.</p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-fig-0001" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-AFig-FIG01.png?filename=nCD008721-AFig-FIG01.ppt&amp;title=1&amp;caption=Results%20from%20searching%20for%20studies%20for%20inclusion%20in%20the%20review.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-0002"><img data-id="CD008721-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG02.png" alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-fig-0002" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-AFig-FIG02.png?filename=nCD008721-AFig-FIG02.ppt&amp;title=2&amp;caption=Risk%20of%20bias%20graph%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20presented%20as%20percentages%20across%20all%20included%20studies.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-0003"><img data-id="CD008721-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG03.png" alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-fig-0003" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-AFig-FIG03.png?filename=nCD008721-AFig-FIG03.ppt&amp;title=3&amp;caption=Risk%20of%20bias%20summary%3A%20review%20authors%27%20judgements%20about%20each%20risk%20of%20bias%20item%20for%20each%20included%20study.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG03.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-0004"><img data-id="CD008721-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG04.png" alt="Forest plot of comparison: 1 Anti‐vascular endothelial growth factor (anti‐VEGF) versus photocoagulation, outcome: 1.3 Visual acuity [logMAR]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anti‐vascular endothelial growth factor (anti‐VEGF) versus photocoagulation, outcome: 1.3 Visual acuity [logMAR]. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-fig-0004" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-AFig-FIG04.png?filename=nCD008721-AFig-FIG04.ppt&amp;title=4&amp;caption=Forest%20plot%20of%20comparison%3A%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20versus%20photocoagulation%2C%20outcome%3A%201.3%20Visual%20acuity%20%5BlogMAR%5D.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG04.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-0005"><img data-id="CD008721-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG05.png" alt="Forest plot of comparison: 2 Anti‐vascular endothelial growth factor (anti‐VEGF) plus surgery versus surgery alone or surgery plus sham or placebo, outcome: 2.3 Visual acuity [logMAR]."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anti‐vascular endothelial growth factor (anti‐VEGF) plus surgery versus surgery alone or surgery plus sham or placebo, outcome: 2.3 Visual acuity [logMAR]. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-fig-0005" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-AFig-FIG05.png?filename=nCD008721-AFig-FIG05.ppt&amp;title=5&amp;caption=Forest%20plot%20of%20comparison%3A%202%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20plus%20surgery%20versus%20surgery%20alone%20or%20surgery%20plus%20sham%20or%20placebo%2C%20outcome%3A%202.3%20Visual%20acuity%20%5BlogMAR%5D.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-AFig-FIG05.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00101"><img data-id="CD008721-fig-00101" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-01.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 1 Visual acuity."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 1 Visual acuity. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00101" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-01.png?filename=nCD008721-CMP-001-01.ppt&amp;title=1.1&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%201%20Visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00102"><img data-id="CD008721-fig-00102" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-02.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 2 Regression of proliferative diabetic retinopathy."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 2 Regression of proliferative diabetic retinopathy. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00102" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-02.png?filename=nCD008721-CMP-001-02.ppt&amp;title=1.2&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%202%20Regression%20of%20proliferative%20diabetic%20retinopathy.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00103"><img data-id="CD008721-fig-00103" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-03.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 3 Presence of vitreous or pre‐retinal haemorrhage."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 3 Presence of vitreous or pre‐retinal haemorrhage. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00103" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-03.png?filename=nCD008721-CMP-001-03.ppt&amp;title=1.3&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%203%20Presence%20of%20vitreous%20or%20pre%E2%80%90retinal%20haemorrhage.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00104"><img data-id="CD008721-fig-00104" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-04.png" alt="Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 4 Adverse effects."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone, Outcome 4 Adverse effects. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00104" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-001-04.png?filename=nCD008721-CMP-001-04.ppt&amp;title=1.4&amp;caption=Comparison%201%20Anti%E2%80%90vascular%20endothelial%20growth%20factor%20%28anti%E2%80%90VEGF%29%20with%20or%20without%20panretinal%20photocoagulation%20%28PRP%29%20versus%20PRP%20alone%2C%20Outcome%204%20Adverse%20effects.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-001-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00201"><img data-id="CD008721-fig-00201" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-01.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 1 Loss of 3 or more lines of ETDRS visual acuity."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 1 Loss of 3 or more lines of ETDRS visual acuity. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00201" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-01.png?filename=nCD008721-CMP-002-01.ppt&amp;title=2.1&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%201%20Loss%20of%203%20or%20more%20lines%20of%20ETDRS%20visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-01.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00202"><img data-id="CD008721-fig-00202" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-02.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 2 Gain of 3 or more lines of ETDRS visual acuity."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 2 Gain of 3 or more lines of ETDRS visual acuity. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00202" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-02.png?filename=nCD008721-CMP-002-02.ppt&amp;title=2.2&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%202%20Gain%20of%203%20or%20more%20lines%20of%20ETDRS%20visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-02.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00203"><img data-id="CD008721-fig-00203" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-03.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 3 Visual acuity."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 3 Visual acuity. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00203" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-03.png?filename=nCD008721-CMP-002-03.ppt&amp;title=2.3&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%203%20Visual%20acuity.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-03.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00204"><img data-id="CD008721-fig-00204" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-04.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 4 Presence of vitreous or pre‐retinal haemorrhage."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 4 Presence of vitreous or pre‐retinal haemorrhage. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00204" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-04.png?filename=nCD008721-CMP-002-04.ppt&amp;title=2.4&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%204%20Presence%20of%20vitreous%20or%20pre%E2%80%90retinal%20haemorrhage.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-04.png">Open in new tab</a></div> </div> <div class="figure" id="CD008721-fig-00205"><img data-id="CD008721-fig-00205" src="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-05.png" alt="Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 5 Adverse effects."> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab with vitrectomy compared with vitrectomy alone, Outcome 5 Adverse effects. </p> </div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-fig-00205" class="figureList">Navigate to figure in Review</a><button href="#" class="print-figure">Print figure</button><a class="" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/ppt/CDSR/CD008721/image_n/nCD008721-CMP-002-05.png?filename=nCD008721-CMP-002-05.ppt&amp;title=2.5&amp;caption=Comparison%202%20Bevacizumab%20with%20vitrectomy%20compared%20with%20vitrectomy%20alone%2C%20Outcome%205%20Adverse%20effects.&amp;citation=Martinez%E2%80%90Zapata MJ, Mart%C3%AD%E2%80%90Carvajal AJ, Sol%C3%A0 I, Pijo%C3%A1n JI, Buil%E2%80%90Calvo JA, Cordero JA, Evans JR. Anti%E2%80%90vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, 11. Art. No.: CD008721. DOI: http://dx.doi.org/10.1002/14651858.CD008721.pub2"> Download as PowerPoint </a><a class="figure-viewer-isolate" target="_blank" href="/cdsr/doi/10.1002/14651858.CD008721.pub2/media/CDSR/CD008721/image_n/nCD008721-CMP-002-05.png">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008721-tbl-0001" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Anti‐VEGF with or without laser (panretinal photocoagulation; PRP) compared with PRP alone for proliferative diabetic retinopathy</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Anti‐VEGF with or without laser (panretinal photocoagulation; PRP) compared with PRP alone for proliferative diabetic retinopathy</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people with PDR </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> anti‐VEGF with or without PRP </p> <p><b>Comparison:</b> PRP </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>PRP</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anti‐VEGF with or without PRP</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Loss of</b> ≥ <b>3 lines of ETDRS visual acuity</b> <br> Follow‐up: 12 months </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>300 per 1000</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>57 per 1000 (15 to 243)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.19</b> (0.05 to 0.81) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61 (1 study)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊝⊝⊝<br> <b>very low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Gain of</b> ≥ <b>3 lines of ETDRS visual acuity</b> <br> Follow‐up: mean 12 months </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>10 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>68 per 1000 (4 to 1260)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 6.78</b> (0.37 to 125.95) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61 (1 study)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>very low</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Visual acuity</b> <br> logMAR </p> <p>(logMAR scale value of 0 = 6/6 vision, higher score = worse vision)</p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity ranged across control groups from<br> <b>0.08 to 0.72 logMAR</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity in the intervention groups was<br> <b>0.07 logMAR units lower</b> <br> (0.12 to 0.02 lower) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>373 (5 studies)</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>low</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Regression of proliferative diabetic retinopathy</b> (as measured by area of fluorescein leakage) </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>In 1 trial, people who received bevacizumab in addition to PRP had more regression of PDR, as measured by area of fluorescein leakage at 6 months compared with people who had PRP alone (MD ‐8.13 mm<sup>2</sup>, 95% CI ‐10.94 mm<sup>2</sup> to ‐5.32 mm<sup>2</sup>, 19 participants). In another trial, people who received ranibizumab in addition to PRP had more regression of PDR, as measured by change in area of fluorescein leakage between baseline and 12 months compared with people who had PRP alone, however, the size of the effect was smaller and the CIs were compatible with no effect, or less regression (MD ‐1.0 mm<sup>2</sup>, 95% CI ‐5.3 mm<sup>2</sup> to 3.3 mm<sup>2</sup>, 20 participants) </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Presence of vitreous/pre‐retinal haemorrhage</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>150 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>48 per 1000 (24 to 98)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.32 (</b>95% CI 0.16 to 0.65) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>342 (3 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quality of life</b> </p> </td> <td align="" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>No data reported on quality of life</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>Adverse effects were reported in 3 studies: 1 study of bevacizumab plus PRP compared with PRP alone and followed up to 3 months (61 participants); 1 study of ranibizumab compared with saline (both groups received PRP if indicated) and followed up to 4 months (261 participants); 1 study of ranibizumab plus PRP compared with PRP alone and followed up to 12 months (31 participants) </p> <p> <ul id="CD008721-lst1-0019"> <li> <p>Neovascular glaucoma: RR 1.09 (95% CI 0.07 to 17.21; 1 RCT, 261 participants)</p> </li> <li> <p>Retinal detachment: RR 0.99 (95% CI 0.44 to 2.25; 1 RCT, 261 participants)</p> </li> <li> <p>Cataract: RR 0.32 (95% CI 0.01 to 7.63; 1 RCT, 61 participants)</p> </li> <li> <p>Raised intraocular pressure: 2 different estimates from 2 trials: RR 0.11 (95% CI 0.01 to 1.92; 1 RCT, 61 participants) and RR 0.92 (95% CI 0.49 to 1.70; 1 RCT, 261 participants) </p> </li> <li> <p>Cerebrovascular accident: RR 3.26 (95% CI 0.13 to 79.34; 2 RCTs, 322 participants)</p> </li> <li> <p>Endophthalmitis: RR 0.36 (95% CI 0.01 to 8.82; 1 RCT, 261 participants) ‐ but unusual trial as control group received injection of saline, only case of endophthalmitis </p> </li> <li> <p>Arterial hypertension: RR 0.47 (95% CI 0.12 to 1.76; 1 RCT, 261 participants)</p> </li> <li> <p>Pain score: MD ‐56.1 (95% CI ‐71.9 to ‐40.3; 1 RCT, 31 participants) in favour of ranibizumab compared with PRP </p> </li> </ul> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <b>CI:</b> confidence interval; <b>ETDRS:</b> Early Treatment Diabetic Retinopathy Study; <b>MD:</b> mean difference; <b>PDR:</b> proliferative diabetic retinopathy; <b>PRP:</b> panretinal photocoagulation; <b>RR:</b> risk ratio; <b>VEGF:</b> vascular endothelial growth factor. </p> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><sup>1</sup> Downgraded for risk of bias (‐1) (study at high risk of selective reporting bias) imprecision (‐1) (wide CIs) and indirectness (‐1) (study reported gain/loss of ≥ 2 lines at 3 months only).<br> <sup>2</sup> Downgraded for risk of bias (‐1) (3 studies at high risk of bias in ≥ 1 domains) and downgraded for indirectness (‐1) (only 1 of the studies followed up to 12 months). </p> <p><sup>3</sup> Downgraded for risk of bias (‐1) (2 studies at high risk of bias in ≥ 1 domain) and downgraded for indirectness (‐1) (no study reported at 12 months). </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span>&nbsp;<span class="table-title">Anti‐VEGF with or without laser (panretinal photocoagulation; PRP) compared with PRP alone for proliferative diabetic retinopathy</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-tbl-0001" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008721-tbl-0002" class="summary-of-findings framed"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Bevacizumab before or during vitrectomy compared with vitrectomy alone</span></div> <tbody> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Bevacizumab before or during vitrectomy compared with vitrectomy alone</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><b>Patient or population:</b> people undergoing vitrectomy for PDR </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> bevacizumab before or during vitrectomy </p> <p><b>Comparison:</b> vitrectomy alone or vitrectomy with sham injection </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Outcomes</b> </p> </td> <td align="" valign="top" colspan="2" rowspan="1" class="table-tint table-highlight"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Relative effect<br> (95% CI)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>No of participants<br> (studies)</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="3" class="table-header"> <p><b>Quality of the evidence<br> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Assumed risk</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Surgery</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>Anti‐VEGF plus surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Loss of</b> ≥ <b>3 lines of ETDRS visual acuity</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>60 per 1000</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>29 per 1000</b> <br> (5 to 188) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 0.49</b> <br> (0.08 to 3.14) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94<br> (3 studies) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> low<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Gain of</b> ≥ <b>3 lines of ETDRS visual acuity</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>500 per 1000</b> </p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p><b>810 per 1000</b> <br> (600 to 1000) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>RR 1.62</b> <br> (1.2 to 2.17) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94<br> (3 studies) </p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> low <sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Visual acuity</b> </p> <p>logMAR<br> (logMAR scale value of 0 = 6/6 vision, higher score = worse vision) </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity ranged across control groups from<br> <b>0.51 to 1.46 logMAR units</b> </p> </td> <td align="" valign="top" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>The mean visual acuity in the intervention groups was<br> <b>0.24 logMAR units lower</b> <br> (0.50 lower to 0.01 higher) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐</p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>335<br> (6 studies) </p> </td> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>low</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Regression of PDR</b> (as measured by area of fluorescein leakage) </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>No data reported on regression of PDR</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Presence of vitreous/pre‐retinal haemorrhage</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>500 per 1000</p> </td> <td align="" valign="" colspan="1" rowspan="1" class="table-tint table-highlight"> <p>150 per 1000 (90 to 260)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>RR 0.30 (0.18 to 0.52)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>393 (7 studies)</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>⊕⊕⊝⊝<br> <b>low</b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Quality of life</b> </p> </td> <td align="" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>No data reported on quality of life</p> </td> </tr> <tr class="separated"> <td align="" valign="top" colspan="1" rowspan="1" bgcolor="#ffffff"> <p><b>Adverse effects</b> </p> </td> <td align="" valign="" colspan="5" rowspan="1" class="table-tint table-highlight"> <p>Neovascular glaucoma: RR 2.33 (95% CI 0.28 to 19.17; 1 RCT, 368 participants)</p> <p>Retinal detachment: RR 0.56 (95% CI 0.11 to 2.86; 3 RCTs, 182 participants)</p> <p>Cataract: RR 0.68 (95% CI 0.38 to 1.23; 2 RCTs, 137 participants)</p> <p>Raised intraocular pressure: RR 0.31 (95% CI 0.01 to 7.47; 1 RCT, 68 participants)</p> <p>Myocardial infarction: no events in 2 trials (175 participants)</p> <p>Cerebrovascular accident: no events in 2 trials (175 participants)</p> <p>Endophthalmitis: none of the studies reported endophthalmitis</p> <p>Arterial hypertension: none of the studies reported arterial hypertension</p> <p>Pain: none of the studies reported pain</p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br> <b>CI:</b> confidence interval; <b>ETDRS:</b> Early Treatment Diabetic Retinopathy Study; <b>PDR:</b> proliferative diabetic retinopathy; <b>RR:</b> risk ratio; <b>VEGF:</b> vascular endothelial growth factor. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p>GRADE Working Group grades of evidence<br> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> <tr class="separated"> <td align="" valign="" colspan="6" rowspan="1" bgcolor="#ffffff"> <p><sup>1</sup> Downgraded for imprecision (‐1) (wide CIs) and downgraded for indirectness (‐1) (only 1 trial reported at 12 months and only 1 (other) trial reported loss of ≥ 3 lines).<br> <sup>2</sup> Downgraded for indirectness (‐1) (only 1 trial reported at 12 months and only 1 (other) trial reported gain of ≥ 3 lines) and downgraded for inconsistency (‐1) (I<sup>2</sup> = 73%). </p> <p><sup>3</sup>Downgraded for risk of bias (‐1) (2 studies at high risk of bias in ≥ 1 domains) and downgraded for inconsistency (‐1) (I<sup>2</sup> = 66%). </p> <p><sup>4</sup> Downgraded for risk of bias (‐1) (2 studies at high risk of bias in ≥ 1 domains, 3 studies at unclear risk of bias in ≥ 3 domains) and downgraded for indirectness (‐1) (only 1 study reported at 12 months). </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span>&nbsp;<span class="table-title">Bevacizumab before or during vitrectomy compared with vitrectomy alone</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-tbl-0002" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008721-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">ETDRS classification of diabetic retinopathy</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mild</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Presence of at least 1 microaneurysm</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Moderate</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Haemorrhages or microaneurysms (or both) more than standard photo 2A, presence of soft exudates, venous beading, IRMA definitively present </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Severe</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Haemorrhages or microaneurysms (or both) more than standard photo 2A in all 4 quadrants, or venous beading in ≥ 2 quadrants, or IRMA more than standard photo 8A in at least 1 quadrant </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Very severe</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Any ≥ 2 of the changes seen in severe NPDR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Early PDR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Presence of new vessels</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>High‐risk PDR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Any of the following: NVD more than one‐third to one‐quarter disc diameter, NVD less than one‐third to one‐quarter disc diameter with vitreous or pre‐retinal haemorrhage, new vessels elsewhere with vitreous or pre‐retinal haemorrhage </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ETDRS: Early Treatment Diabetic Retinopathy Study; IRMA: intraretinal microaneurysm; NPDR: non‐proliferative diabetic retinopathy; NVD: new vessels at optic disc; PDR: proliferative diabetic retinopathy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span>&nbsp;<span class="table-title">ETDRS classification of diabetic retinopathy</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-tbl-0005" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008721-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">ICDRDS scale</span></div> <tbody> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Non‐apparent retinopathy</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No abnormalities</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mild NPDR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Microaneurysms only</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Moderate NPDR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>More than just microaneurysms but less than severe NPDR</p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Severe NPDR</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Any of the following: &gt; 20 intraretinal haemorrhages in each of 4 quadrants; definite venous beading in 2 quadrants; prominent intraretinal microvascular abnormalities in 1 quadrant a<i>nd no</i> signs of proliferative retinopathy </p> </td> </tr> <tr> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Proliferative diabetic retinopathy</p> </td> <td align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>≥ 1 of the following: neovascularisation, vitreous or pre‐retinal haemorrhage</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>ICDRDS: International Clinical Diabetic Retinopathy Disease Severity scale; NPDR: non‐proliferative diabetic retinopathy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span>&nbsp;<span class="table-title">ICDRDS scale</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/full#CD008721-tbl-0006" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008721-tbl-0003" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>373</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.07 [‐0.12, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.1 Pegaptanib</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>16</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.06 [‐0.22, 0.10]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.2 Bevacizumab</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>80</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.01 [‐0.11, 0.09]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.3 Ranibizumab</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>277</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.10 [‐0.16, ‐0.03]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Regression of proliferative diabetic retinopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Presence of vitreous or pre‐retinal haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>342</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.32 [0.16, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.1 Bevacizumab</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.11 [0.01, 1.92]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.2 Pegaptanib</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>20</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.2 [0.01, 3.70]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.3 Ranibizumab versus control</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.38 [0.18, 0.81]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.1 Neovascular glaucoma</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.09 [0.07, 17.21]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.2 Retinal detachment</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.99 [0.44, 2.25]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.3 Cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>61</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.32 [0.01, 7.63]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.4 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>322</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.75 [0.42, 1.36]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.5 Cerebrovascular accident</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>322</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3.26 [0.13, 79.34]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.6 Endophalmitis</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.36 [0.01, 8.82]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>4.7 Arterial hypertension</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>261</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.47 [0.12, 1.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span>&nbsp;<span class="table-title">Anti‐vascular endothelial growth factor (anti‐VEGF) with or without panretinal photocoagulation (PRP) versus PRP alone</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-tbl-0003" class="tableList">Navigate to table in Review</a></div> </div> <div class="table"> <table data-id="CD008721-tbl-0004" class="comparison"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Bevacizumab with vitrectomy compared with vitrectomy alone</span></div> <thead> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Outcome or subgroup title</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of studies</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>No. of participants</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Statistical method</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">1 Loss of 3 or more lines of ETDRS visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.49 [0.08, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">2 Gain of 3 or more lines of ETDRS visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>94</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1.62 [1.20, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">3 Visual acuity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>6</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>335</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>‐0.24 [‐0.50, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">4 Presence of vitreous or pre‐retinal haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>7</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>393</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.30 [0.18, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i class="fa fa-caret-down" aria-hidden="true"></i></span></p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"></td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.1 Neovascular glaucoma</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>107</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2.33 [0.28, 19.17]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.2 Retinal detachment</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>3</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>182</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.56 [0.11, 2.86]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.3 Cataract</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>137</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.68 [0.38, 1.23]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.4 Raised intraocular pressure</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>1</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>68</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.31 [0.01, 7.47]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.5 Myocardial infarction</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>175</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.6 Cerebrovascular accident</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>2</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>175</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td data-title="Outcome or subgroup title" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>5.7 Arterial hypertension</p> </td> <td data-title="No. of studies" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td data-title="No. of participants" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0</p> </td> <td data-title="Statistical method" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td data-title="Effect size" align="" valign="" colspan="1" rowspan="1" bgcolor="#ffffff"> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span>&nbsp;<span class="table-title">Bevacizumab with vitrectomy compared with vitrectomy alone</span></div> </div> <div class="tools"><a href="/cdsr/doi/10.1002/14651858.CD008721.pub2/references#CD008721-tbl-0004" class="tableList">Navigate to table in Review</a></div> </div> </div> <section class="translation-notes-modal" style="display: none" data-modal-title="Translation notes" data-modal-class="translation-notes" data-ok-btn-selector=".ok-btn"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008721-note-1204">Español</a> </li> <li class="section-language"> <a class="" href="ru#CD008721-note-1203">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" id="citeProcText" data-load-error="Unable to load citation data"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a href="#" class="addthis_button_citeulike at300b btn btn-link">CiteULike</a></li> <li><a href="#" class="addthis_button_mendeley at300b btn btn-link">Mendeley</a></li> <li><a href="#" class="citation-btn-refworks at300b btn btn-link" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <h4>Copy or download citation</h4> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button type="button" class="btn btn-link">Plain text</button></li> <li class="citation-option" data-option="endnote"><button type="button" class="btn btn-link">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button type="button" class="btn btn-link">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button type="button" class="btn btn-link">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button type="button" class="btn btn-link">BibteX</button></li> </nav> <div class="citation-content"> <pre id="citationContent" tabindex="0" data-load-error="Unable to load citation data"></pre> </div> <div class="clearfix"> <form class="download-citation-form" method="GET" target="citation-download-iframe" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=citation-citeproc&p_p_cacheability=cacheLevelPage&p_p_col_id=column-1&p_p_col_count=1"> <input type="hidden" id="siteId" name="siteId" value="" /> <input type="hidden" id="downloadType" name="downloadType" value="" /> <input type="hidden" id="style" name="style" value="" /> <input type="hidden" id="articleId" name="articleId" value="" /> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay" /><input name="p_p_lifecycle" type="hidden" value="2" /><input name="p_p_state" type="hidden" value="normal" /><input name="p_p_mode" type="hidden" value="view" /><input name="p_p_resource_id" type="hidden" value="citation-download" /><input name="p_p_cacheability" type="hidden" value="cacheLevelPage" /><input name="p_p_col_id" type="hidden" value="column-1" /><input name="p_p_col_count" type="hidden" value="1" /> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withAbstract"> <input class="checkbox" type="checkbox" name="withAbstract" /> <span class="checkbox-label">Include abstract</span> </label> </div> </form> <iframe title="Citation download frame" name="citation-download-iframe" src="" style="display: none; visibility: hidden" aria-hidden="true"></iframe> </div> </div> </div> </div> <div class="print-modal" style="display: none;" data-modal-title="Print this review"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input title="Select/deselect all" type="checkbox" class="print-options-select-all" checked="checked" /> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i class="fa fa-print" aria-hidden="true"></i> Print</button> </div> </div> <div class="download-stats-data-modal" style="display: none;" data-modal-title="Download statistical data"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <p> Downloaded data can only be viewed using <a class="external" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/tools/review-production-tools/revman-5" target="_blank">Review Manager software.</a> </p> <p> Please note that: <ul> <li>data are only available for Cochrane Reviews that contain one or more forest plots; and</li> <li>data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.</li> </ul> </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input type="hidden" name="content-disposition" value="attachment" /> <input type="hidden" name="mime-type" value="application/octet-stream" /> <p class="print-options-controls"> <input type="checkbox" class="download-stats-data-toc-check-box" aria-label="I agree to these terms and conditions" /> <span class="checkbox-label" aria-hidden="true">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i class="fa fa-download" aria-hidden="true"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" style="display:none;" data-modal-title="Share this review"> <div class="add-this"> <div class="addthis_toolbox addthis_default_style addthis_32x32_style"> <nav class="stacked-nav-list"> <li> <a href="#" class="addthis_button_twitter at300b" title="Tweet">Twitter</a> </li> <li> <a href="#" class="addthis_button_mendeley at300b" target="_blank" title="Mendeley">Mendeley</a> </li> <li> <a href="#" class="addthis_button_facebook at300b" title="Facebook">Facebook</a> </li> <li> <a href="#" class="addthis_button_linkedin at300b" target="_blank" title="LinkedIn">LinkedIn</a> </li> <li> <a href="#" class="addthis_button_email at300b" target="_blank" title="Email">Email</a> </li> <li> <a href="#" class="addthis_button_whatsapp at300b" target="_blank" title="WhatsApp">WhatsApp</a> </li> <li class="clearfix"> <a href="#" class="addthis_button_more btn primary pull-right" target="_blank" title="View more"> <i class="fa fa-plus" aria-hidden="true"></i> View more</a> </li> </ul> </div> </div> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button type="button" class="btn btn-link" id="figureOptionBtn">Figures</button></li> <li class="table-options-btn-container"><button type="button" class="btn btn-link" id="tableOptionBtn">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div id="figureThumbnails" class="figure-thumbnails is-visible"></div> <div id="tableThumbnails" class="table-thumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a href="#" class="figure-viewer-menu-toggle"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-table-show-text="Show table list" data-table-hide-text="Hide table list" data-figure-show-text="Show thumbnails" data-figure-hide-text="Hide thumbnails">Hide thumbnails</span> </a> <a href="#" class="figure-viewer-zoomin"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a href="#" class="figure-viewer-zoomout"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a href="#" class="figure-viewer-nav previous"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a href="#" class="figure-viewer-nav next"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_  portlet-static portlet-static-end kaleo-designer-portlet " id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a title="Cochrane logo" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/">
<img class="footer-logo logo-part-1" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-1.png" alt="Cochrane logo" /> <img class="footer-logo logo-part-2" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/footer-logo-part-2.png" alt="" /> </a> </div> <nav class="footer-links"> <ul class="root"> <li class="footer-item"> <a class="footer-item-link" href="/about-cochrane1">About Cochrane</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/evidence" target="_blank">Cochrane.org</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us" target="_blank">Who we are</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NJYXT5SPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Get involved</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX665WNWTYE63PMNYXG4DTMFYGKLUQPJUB/" target="_blank">Consumer Network</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-funders-and-partners" target="_blank">Partners</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYXZ5DQPF4XT7LNF3SX8Z5IPJRX63JPN73GH/" target="_blank">Colloquium</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news" target="_blank">In the news</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/publications">Publications</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="/library">Cochrane Library</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/" target="_blank">Library Homepage</a> </li> <li class="footer-item"> <a class="footer-item-link" href="cdsr/about-cdsr" target="_blank">Cochrane Reviews (CDSR)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/central" target="_blank">Trials (CENTRAL)</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cca/about" target="_blank">Cochrane Clinical Answers</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/cochrane-library-app" target="_blank">Cochrane Library App</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/cdsr/journal-club" target="_blank">Journal Club</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/about/podcasts" target="_blank">Podcasts</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/community">Community</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/" target="_blank">Community</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MF3GG4DJMVYGG55DNB3GC5UFF3YYE3D/" target="_blank">Archie log-in</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/PS3GC4LPNFYGPLUDN7SXR6UBN3TT655TMH/" target="_blank">Training and support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/NWTYI4DQMS3T6Z5QMNVHEZLPMVYG86UH/" target="_blank">Methods</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/help" target="_blank">Software</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/news/jobs" target="_blank">Jobs and opportunities</a> </li> </ul> </li> <li class="footer-item"> <a class="footer-item-link" href="/contact-us">Contact Us</a> <ul class="child"> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/contact" target="_blank">General enquiries</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/help/contact-us" target="_blank">Cochrane Library support</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/chief-executive-officers-office/team" target="_blank">Chief Executive Officer</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MNYX45LWN3VYI8JPMNYXG4DTMFYGKLUQPJUB/organizational-info/people/central-executive-team/editorial-methods/team" target="_blank">Editor in Chief</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TT655TMH/about-us/our-global-community" target="_blank">Cochrane groups</a> </li> <li class="footer-item"> <a class="footer-item-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/media" target="_blank">Media</a> </li> <li class="footer-item"> <a class="footer-item-link" href="/accessibility" target="_blank">Accessibility</a> </li> </ul> </li> </ul> </nav> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/advertisers">Advertisers & Agents</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/NB4XELUYNFXGK8JPMNYXN/community/support/cochrane-library">Help & Support</a></li> <li><a class="aux-footer-nav-link" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/terms-and-conditions">Terms & Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright &copy; 2000 - 2020 by <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUYNFXGK8JPMNYXN/" class="">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br /> Review our <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUYNFXGK8JPMNYXN/en-gb/privacy"><strong>Privacy Policy</strong></a> </p> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/MW4T675JNSTYTLUDN7XB/"><img class="logo" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/en-US_wiley-footer-logo.png" alt="Wiley logo" /></a> </div> </div> <span class="wiley-semi-circle"></span> </div> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" style="display: none" data-modal-title="Feature in English only" data-modal-class="english-only-modal"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="/cochrane-theme/vendor/ie9.js?t=1581422282000" type="text/javascript"></script> <!--<![endif]--> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/theme.js?t=1581422282000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/checkout.js"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MNYX67DFN34C66UFMFTGG7LCMVYGG55N/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MN3G865UNWRYE43NMNTG6LUDPJYYG65TMWUC655TMH/widget/v2.0/widget.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/MRZXE8DIHB4XC63SNWYHPN3PMNXG87LEM33G85UVF3YGK7A/assets/embed.js" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718153000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718249000" type="text/javascript"></script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581718173000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008721\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008721\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008721\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dreferences\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dreferences\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008721\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008721\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1581422282000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a href="#" class="rh-nav-close-btn"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a href="#" class="rh-nav-open-btn"> <span>Review tools & navigation</span> </a> </div> <iframe title="Print frame" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" aria-hidden="true"></iframe> <div class="mobile-navigation"> <div class="close-container"> <a href="#" class="main-nav-back-btn" aria-label="Navigate back"><i class="fa fa-chevron-left"></i></a> <a href="#" class="main-nav-close-btn" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end " id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img id="ymag__null__null" src="/scolaris-search/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_auth=EfT7x5RD&p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=1&p_p_state=normal&p_p_mode=view&_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input type="hidden" name="searchType" value="basic" /> <input type="hidden" name="facetDisplayName" value="" /> <input type="hidden" name="facetQueryTerm" value="" /> <input type="hidden" name="facetQueryField" value="" /> <input type="hidden" name="facetCategory" value="" /> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select title="Search by options" aria-label="Search by options" name="searchBy" class="custom-select-enabled search-type"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" style="display: none;" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=topics-list&p_p_cacheability=cacheLevelPage"> <select class="search-select-topic-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input type="text" size="30" class="field browser-search search-text ui-autocomplete-input" value="" aria-label="Enter search term" id="searchText" name="searchText" placeholder="Search">
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button type="submit" class="searchByBtn" aria-label="Search">
<i class="fa fa-search" aria-hidden="true"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=references&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008721.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008721.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<a href="/en/browse-by-topic" class="btn secondary">Browse </a>
<a href="/en/advanced-search" class="btn secondary advanced-search-button">Advanced search</a>
</div>
<div class="menu-items parent">
<ul>
<li class="nav-root-item parent">
<a href="#" title="Select language" class="language-selection-title-link">
<span class="mobile-nav-language-title">Select your preferred language</span><span class="icon fa fa-caret-down"></span>
<ul class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_  portlet-static portlet-static-end  " id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">

<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img id="fdkn__null__null" src="/scolaris-language-portlet/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hr, ja, ko, ms, pl, pt, ru, ta, th, zh, za]"> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-file-text"></i> English </a> <a title="Select your preferred language" class="language-select-mobile" href="#"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane Review language</h3> <p>Select your preferred language for Cochrane Reviews. You will see translated Review sections in your preferred language. Sections without translation will be in English.</p> <div id="active-content-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de" class="content-language-selector " data-languagecode="de">Deutsch</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en" class="content-language-selector is-active" data-languagecode="en">English</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es" class="content-language-selector " data-languagecode="es">Español</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa" class="content-language-selector " data-languagecode="fa">فارسی</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr" class="content-language-selector " data-languagecode="fr">Français</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr" class="content-language-selector " data-languagecode="hr">Hrvatski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja" class="content-language-selector " data-languagecode="ja">日本語</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko" class="content-language-selector " data-languagecode="ko">한국어</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms" class="content-language-selector " data-languagecode="ms">Bahasa Malaysia</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl" class="content-language-selector " data-languagecode="pl">Polski</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt" class="content-language-selector " data-languagecode="pt">Português</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru" class="content-language-selector " data-languagecode="ru">Русский</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta" class="content-language-selector " data-languagecode="ta">தமிழ்</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th" class="content-language-selector " data-languagecode="th">ภาษาไทย</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh" class="content-language-selector " data-languagecode="zh">简体中文</a> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage&_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=za" class="content-language-selector " data-languagecode="za">繁體中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div id="active-portal-language" class="dropdown-trigger"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a href="/en/cdsr/doi/10.1002/14651858.CD008721.pub2/references/en" class="portal-language-selector is-active" data-portallanguage="en">English</a> <a href="/es/cdsr/doi/10.1002/14651858.CD008721.pub2/references/es" class="portal-language-selector " data-portallanguage="es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=set-content-language&p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</ul>
</a>
</li>
<li class="parent">
<a class="mobile-link signin" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/c/portal/login?p_l_id=20757&redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008721.pub2%2Freferences" data-redirect="false" rel="nofollow">
Sign In
</a>
</li>
</ul>
<div class="menu-items-footer">
<div class="utility-links">
<a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/http/P75YPLUDN7SXR6UBN3TT655TMH/" class="cochrane-link" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
<div class="basic-login-form-content" style="display: none;" data-modal-title="Sign in">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="dbam__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1583245518670" /> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value="" /> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true" /> <input checked class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onClick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true" /> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> <a href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/N7YGZ4LPMWXGTZUTMF3HTLUYNFXGK8JPMNYXN/user-registration" target="_blank" class="btn secondary">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" style="display: none;" data-modal-title="Institutional login">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="obft__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text">
</div>
<button class="btn primary" type="submit" name="button">Go</button>
</div>
<div id="institutionLookupErrorDiv" class="message error" style="display:none">
'<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
</div>
</div>
<input type="hidden" id="entityId" name="entityId" value="">
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_  portlet-static portlet-static-end portlet-login " id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img id="joiu__null__null" src="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/cochrane-theme/images/spacer.png" alt="" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;" /> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="http://eproxy2.lib.tsinghua.edu.cn:80/rwt/297/https/P75YPLUDN7SXR6UBN3TXZ4LCPJRYE8JPMNYXN/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" class="form sign-in-form " id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm" autocomplete="on"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1583245518673" /> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false" /> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="&#x2f;cdsr&#x2f;doi&#x2f;10&#x2e;1002&#x2f;14651858&#x2e;CD008721&#x2e;pub2&#x2f;references" /> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false" /> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value="" /> </div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value="" /> </div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true" /> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button type="submit" class="btn primary">Sign in</button> </div> </div> </fieldset> </form> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'>
<input type="hidden" name="openlabel" id="openlabel" value='Open access'>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" style="display: none;" data-modal-title="Unlock the potential of Cochrane evidence">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_  portlet-static portlet-static-end scolaris-content-display-portlet " id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img id="wpdq__null__null" src="/scolaris-content-display/icon.png" alt="" /> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class=" portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form method="post" action="/shibboleth" id="institutionLoginForm"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" name="institutionName" id="institutionName" value="" type="text"> </div> <button class="btn primary" type="submit" name="button">Go</button> </div> <div id="institutionLookupErrorDiv" class="message error" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input type="hidden" id="entityId" name="entityId" value=""> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input type="hidden" name="freelabel" id="freelabel" value='Free access'> <input type="hidden" name="openlabel" id="openlabel" value='Open access'> </div> </section> </div> </div>  <script>window.urlTitle="/cdsr/doi/10.1002/14651858.CD008721.pub2";addthis_config={pubid:"ra-593597d01cdf9a55",ui_508_compliant:true};addthis_share={url:window.location.href,title:document.title};</script> <script src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-593597d01cdf9a55"></script> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> </body> </html> 